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Methylglyoxal (MGO), a highly reactive dicarbonyl compound formed as 
by-product of glycolysis, is an ubiquitous metabolite of cellular metabolism. 
Therefore, it is produced in all cells, both under normal and pathological 
conditions. Under physiological circumstances, MGO is detoxified through 
the glyoxalase system, of which Glyoxalase 1 (Glo1) is the rate limiting 
enzyme. In pathological conditions, as in chronic hyperglycemia, high blood 
glucose levels lead to increased MGO accumulation. It is known that MGO 
plays a major role in endothelial cell damage and development of vascular 
disease. We have previously demonstrated that MGO induces endothelial 
insulin resistance both in vitro and in animal models. In the last few years, 
many evidence has provided a link between microRNAs (miRNAs) and 
diabetic complications. Indeed, miRNAs regulate cellular molecular 
pathways, including insulin signaling, thus controlling the pathophysiology 
of vascular bed. This study includes the investigation of two aspects of MGO 
effects on the pathophysiology of diabetes mellitus (DM) and its associated 
complications: 1. the evaluation of MGO accumulation on glucose 
homeostasis and vascular function in a mouse model knockdown for Glo1 
(Glo1KD) and 2. the analysis of miRNAs contribution in MGO induced 
damaging effect on insulin responsiveness in mouse aortic endothelial cells 
(MAECs). 
The results obtained in vivo demonstrated that the endogenous accumulation 
of MGO in mice with a reduced expression of Glo1 leads to an age-
dependent development of glucose intolerance, in absence of 
hyperglycemia. Indeed, despite the reduced glucose tolerance at 10 months 
of age, Glo1KD mice have no differences in body weight and in the glucose 
levels, compared to WT mice, neither at 5 months nor at 10 months of age. 
While no alterations in the whole-body insulin-sensitivity have been 
observed by insulin tolerance tests, Glo1KD mice show a basal 
hyperinsulinemia and impaired glucose-stimulated insulin-secretion, 
compared to WT mice. Moreover, an increased systolic blood pressure 
accompanied by impaired endothelium-dependent vasodilation are already 
shown starting from 5 months of age in Glo1KD mice.  
A deeper analysis of the molecular mechanisms involved in the endothelial 
dysfunction has been performed in vitro, in MAECs exposed to MGO, 
which we have previously demonstrated to display insulin resistance and an 
imbalanced production of vasoactive molecules: NO and ET-1. Our results 
demonstrate that MGO induces the down-regulation of 4 out of 84 diabetes-
associated miRNAs. Among these, the reduced expression of miR-190a and 
miR-214 has been validated both in MAECs exposed to MGO and in aortae 
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from Glo1KD mice. The inhibition of miR-190a and miR-214 impairs the 
insulin-induced activation of Akt1/eNOS pathway, whereas their 
overexpression prevents the MGO-induced insulin resistance in MAECs. In 
detail, we have identified the kinase KRAS and the phosphatase PHLPP2 as 
targets of miR-190a and miR-214, respectively.  In MAECs increased 
KRAS levels result from the reduced expression of miR-190a and sustain 
the ERK hyperactivation, which is in turn responsible for the impairment of 
the insulin-stimulated IRS1/Akt/eNOS signal transduction in MAECs 
treated with MGO. Moreover, a reduced insulin-dependent activation of Akt 
in MGO-treated MAECs is fostered by higher protein levels of PHLPP2, 
which we validate here to be a direct target of miR-214.  
In conclusion, our results demonstrate that Glo1 silencing is enough to 
induce MGO accumulation in vivo in Glo1KD mice, causing glucose 
intolerance and β-cell dysfunction, which are characteristic of T2DM 
pathogenesis, together with the impairment of hemodynamic function (i.e 
blood pressure and endothelial-dependent vasodilation), in a context of 
normoglycemia. Moreover, miR-190a and miR-214 play a role in the 
endothelial insulin-resistance induced by MGO in MAECs. Thus, 
representing potential biomarkers of vascular dysfunction. Further efforts in 
the development of pharmacological intervention to interfere with these 
pathogenic events will be useful to provide new therapeutic options aimed 
at preventing the onset and progression of vascular complications in 
diabetes. 
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1. Endothelial cell function 
 
The endothelium was considered to be a selective barrier to the diffusion of 
macromolecules from the vessel lumen to interstitial space. During the past 
years, different studies have highlighted additional roles for the 
endothelium. Indeed, the endothelium regulates vascular tone, cell-cell 
interaction, permeability and the coagulation system through the production 
of several factors, in response to various stimuli (Nigro et al. 2017, 
Schalkwijk et al. 2005). To carry out its above-mentioned functions, the 
endothelium produces components of the extracellular matrix such as 
collagen and a variety of regulatory mediators, including  nitric oxide (NO), 
prostanoids, endothelin-1 (ET-1), angiotensin II (Ang II), tissue-type 
plasminogen activator (t-PA), plasminogen activator inhibitor-1  (PAI-1), 
von Willebrand factor (vWf), adhenosin molecular and cytokines 
(Schalkwijk et al. 2005).  In physiological conditions, the endothelium 
actively decreases vascular tone, limits leucocyte adhesion and, thus, 
inflammatory activity in the vessel wall. It maintains vascular permeability 
to nutrients, hormones, other macromolecules and inhibits platelet adhesion 
and aggregation by producing prostacyclin and NO. Moreover, it limits the 
activation of the coagulation cascade by the thrombomodulin/protein C, 
heparan sulphate/antithrombin and tissue factor/tissue factor pathway 
inhibitor interactions and regulates fibrinolysis by producing t-PA and its 
inhibitor PAI-1. As mentioned above, the endothelium is able to synthesize 
NO, an important molecule that has vasodilator, anti-platelet, anti-
proliferative, permeability-decreasing and anti-inflammatory properties. 
NO inhibits leucocyte adhesion and rolling, as well as cytokine-induced 
expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte 
chemotactic protein-1 (MCP-1), effects that are at least in part attributable 
to the inhibition of the transcription factor nuclear factor κB (NF-κB) 
(Schalkwijk et al. 2005). Disturbing this tightly regulated equilibrium leads 
to endothelial dysfunction (ED). In particular, ED is the first step in the 
initiation, progression and clinical outcome of vascular complications, such 
as retinopathy, nephropathy and hypertension, that are the principal causes 
of mortality and morbidity of diabetic patients (Nigro et al. 2017). Anyway, 
the mechanisms leading to ED are not very completely clarified. Several 
studies have shown that hyperglycemia associated with impaired glucose 
tolerance and diabetes causes insulin resistance and ED (Du et al. 2001). 
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2. Hyperglycemia and endothelial dysfunction 
 
The hallmark of ED is represented by the impaired NO bioavailability. 
Additionally, ED is established when one or more of the following features 
occur: reduced endothelium-mediated vasorelaxation, hemodynamic 
deregulation, impaired fibrinolytic ability, enhanced turnover and /or 
overproduction of growth factors, increased expression of adhesion 
molecules and inflammatory genes, excessive generation of reactive oxygen 
species (ROSs), increased oxidative stress and enhanced permeability of the 
endothelial cells (ECs) layer (Taddei et al. 2003, Addabbo et al. 2009, Sena 
et al. 2013). The increased production of ROSs is due to the activation of 
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase, 
inactivation and reduced expression of the antioxidant enzymes, catalase 
and superoxide dismutase (SOD) or uncoupling of endothelial nitric oxide 
synthase (eNOS) (Dhananjayan et al. 2016). The increased ROSs production 
is one of the factors involved in the activation of transcription factors such 
as NF-κB. NF-κB is a key mediator that regulates multiple pro-
inflammatory and pro-atherosclerotic target genes in ECs, vascular smooth 
muscle cells (VSMCs) and macrophages. Activation of NF-κB leads to an 
increased production of adhesion molecules, leukocyte-attracting 
chemokines and cytokines activating inflammatory cells in the vascular 
wall.  In ED, a pro-thrombotic state is generated by the increased production 
of lesion-based coagulants, such as tissue factor, and the inhibitors of 
fibrinolysis, such as PAI-1. Vascular tone and remodeling are enhanced 
through reduced NO and an increased activity and production of 
vasoconstrictors (i.e. ET-1, angiotensin II, and prostanoids).  
There are several factors contributing to ED, among which the most 
important are: hypertension, smoking, dyslipidemia and hyperglycemia 
(Sena et al. 2013). Hyperglycemia is one of major characteristic of type 2 
diabetes mellitus (T2DM), a common metabolic disease with a high and 
growing prevalence (American Diabetes Association 2009).  In both animal 
and human studies, it has been proven that hyperglycemia impairs 
endothelial function in both macro- and microvascular beds (Sena et al. 
2013). Hyperglycemia causes vascular damage in different cell types of the 
vascular wall through the activation of several  pathways including: 1) the 
increased flux of glucose and other sugars through the polyol pathway; 2) 
the augmented intracellular formation of advanced glycation end products 
(AGEs); 3) the increment of the expression of the receptor for AGEs 
(RAGE); 4) the activation of protein kinase C (PKC) isoforms; and 5) the 
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overactivation of the hexosamine pathway (Fig. 1).  The activation of these 
biochemical ways promotes increased vascular oxidative stress, 
inflammation, apoptosis, atherogenesis and impaired endothelial function 
(Brownlee 2001).  
 
 
 
Figure 1: Molecular pathways activated chronic hyperglycemia. (Schalkwijk and 
Stehouwer 2005). 
 
In hyperglycemic condition, the excess of glucose can be metabolized to 
sorbitol and fructose by aldose reductase (AR) and sorbitol dehydrogenase 
(SDH), respectively. In the hexosamine pathway, fructose 6-phosphate is 
converted into glucosamine 6-phosphate by the enzyme glutamine fructose-
6-phosphate amidotransferase (GFAT) and subsequently into N-
Acetylglucosamine (GlcNAc). The mechanism responsible for the 
activation of PKC by hyperglycemia is related to de novo synthesis of the 
PKC activator, diacylglycerol (DAG) from a stepwise acylation of glycerol 
3-phosphate (G3P). A major pathway activated by increased levels of the 
upstream glycolytic metabolite glyceraldehyde-3-phosphate is the AGEs 
non-enzymatic formation where the major intracellular AGEs precursor 
methylglyoxal (MGO) is generated from triose-phosphates fragmentation. 
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3. Methylglyoxal metabolism 
 
MGO is a highly reactive α-oxaldehyde, whose formation rate depends on 
the organism, tissue, cell metabolism and physiological condition (Igor et 
al. 2015). The endogenous MGO is derived from metabolic intermediates of 
carbohydrates, proteins and fatty acids (Fleming et al. 2011). In mammals, 
the glycolytic pathway is the principal source of MGO via fragmentation of 
triosephosphates G3P and dihydroxyacetone phosphate (DHAP) (Rabbani 
et al. 2016). Under normal physiological conditions, MGO is maintained at 
low levels. The latter are increased in conditions leading to higher 
triosephosphate levels, like happens in hyperglycemia when glucose 
metabolism is increased, in the impairment of pentose pathway with 
decreased G3P or in case of the increased anaerobic glycolysis occurring in 
hypoxia (Nigro et al. 2017). Although the production of MGO constitutes 
only 0.1% of glucotriose flux, its biological effect is important considering 
its high reactivity with proteins and nucleic acids. The irreversible reaction 
of MGO with proteins is directed to arginine residues forming 
hydroimidazolone adducts. The hydroimidazolone (MGO-H1) derived from 
MGO is the most abundant MGO-derived AGEs, as it accounts for >90% of 
all MGO adducts, equivalent to MGO-H1 residues in 1-5% of all proteins 
(Maessen et al. 2015).  
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Figure 2. Pathways involved in MGO formation and detoxification. MGO is generated as 
a byproduct of glycolysis. Other sources of MGO are constitute by: autoxidation of glucose, 
catabolism of threonine and acetone, lipid peroxidation and degradation of glycated 
proteins. MGO is detoxified mainly by the glyoxalase system. Other minor pathways are 
aldehyde dehydrogenase (ALDH) and aldose reductase (AR). Otherwise, it may react with 
amino groups of proteins and other biomolecules to form 1-carboxyethyl-lysine (CEL) 
methylglyoxal-lysine dimer: 1,3-di(Nε-lysino)-4-methyl-imidazolium (MOLD), while it 
forms 2-ammonio-6-{(2-[(4-ammonio-5-oxido-5-oxopentyl)amino]-4-methyl-4,5-dihydro-
1H-imidazol-5-ylidene) amino}hexanoate (MODIC) following dimer crosslink with 
arginine and lysine (Maessen et al. 2015). 
 
Other minor contributors to MGO formation are from the oxidation of 
acetone (Beisswenger et al. 2006), the catabolism of ketone bodies that are 
increased in ketoacidosis (Lyles and Chalmers 1992), lipid peroxidation and 
degradation of glycated proteins and monosaccharides (Kalapos 1999, 
Thornalley et al. 1999) (Fig. 2). It is now known that MGO is observed at 
relative higher plasma levels (2–6 fold) in diabetic patients than in healthy 
subjects and are also found in many food products, beverages and cigarette 
smoke (Nigro et al. 2017). In detail, in physiological conditions, MGO levels 
is 50–150 nM in human plasma and 1–4 μM in human cells. Nevertheless, 
the contribution of exogenous MGO is still controversial. Several studies 
report that free MGO is rapidly degraded during digestion in the intestine 
and, thus, it does not influence plasma levels in vivo (Rabbani et al. 2016, 
Nigro et al. 2017), while others report that in rodents fed with MGO-
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supplemented diet there is a major brain and plasma MGO accumulation 
(Cai et al. 2014). When reactive dicarbonyl concentration increases beyond 
physiological levels, they produce protein and cell dysfunction leading to 
impaired health and disease (Rabbani et al. 2016). 
Under physiological circumstances, MGO is detoxified by different 
mechanisms such us the glyoxalase, aldose reductase, aldehyde 
dehydrogenase and carbonyl reductase pathways (Maessen et al. 2015). 
Undoubtedly, the glyoxalase system, an ubiquitous enzymatic pathway, is 
the main detoxification system for MGO. 
 
4. The glyoxalase pathway 
 
The glyoxalase pathway consists of two enzymes, glyoxalase 1 (Glo1) and 
glyoxalase 2 (Glo2) and a catalytic amount of glutathione (GSH) (Fig. 3). 
 
 
Figure 3. The Glyoxalase System. Glyoxalase system is formed by two enzymes. 
Glyoxalase 1 catalyzes the conversion the MGO-GSH hemi-thioacetal to the thioester S-D-
lactoyglutahione. Glyoxalase 2 catalyzes the hydrolysis of S-D-lactoylglutathione to form 
the end-product D-lactate (Rabbani et al. 2016). 
 
In this process, Glo1 is the most crucial enzyme as it is defined the rate 
limiting enzyme by converting the MGO-GSH hemi thioacetal to the 
thioester S-D-lactoyglutahione (Sousa et al. 2013). Its activity is directly 
proportional to GSH concentration. Thus, when cellular GSH concentration 
declines, as in oxidative stress, there is an associated impairment of Glo1 
activity.  Glo2 is the second enzyme in the glyoxalase system and it 
catalyzes hydrolysis of S-D-lactoylglutathione to D-lactate and GSH 
(Thornalley 1993, Nigro et al. 2017). Glo1 gene is expressed in all tissues 
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of prokaryotic and eukaryotic organisms (Aronsson and Mannervik 1978, 
He et al. 2000), and is the protein localized in the cytoplasmic compartment 
(Rabbani and Thornalley 2014). Several studies demonstrated that Glo1 
activity can be modulated by both gene expression regulation and post-
translational modifications (Ranganathan 1999). While genetic 
polymorphisms of Glo2 are extremely rare, different SNPs (single 
nucleotide polymorphisms) have been identified in the Glo1 gene that 
reduce the Glo1 activity and correlate with an increase of the diabetic 
neuropathy (Groener et al. 2013) and an increase risk of cardiovascular 
complications (Rabbani and Thornalley 2011).  
 
5. MGO and insulin resistance 
 
Insulin resistance is clinically defined as the inability of a known quantity 
of exogenous or endogenous insulin to produce a biological response, as the 
increase of glucose uptake and utilization (Gisela 2005). A widely accepted 
theory states that insulin resistance leads to T2DM, metabolic and 
cardiovascular disease and that MGO may contribute to the pathogenesis of 
insulin resistance (Nigro et al. 2017). We and others have provided evidence 
about the role of MGO on insulin-resistance in major target tissues for 
insulin action (Nigro et al. 2014). For instance, a short exposure of L6 
muscle cells to MGO induces an inhibition of insulin-stimulated 
phosphorylation of protein Kinase B (PKB) and extracellular signal-
regulated protein Kinase 1/2 (ERK1/2), without affecting insulin receptor 
tyrosine phosphorylation (Maessen et al. 2015). Moreover, it has been 
demonstrated that 3T3-L1 adipocyte treated with MGO, it shown an 
impairment of the insulin signalling, as indicated by decreased insulin-
induced insulin receptor substrate (IRS-1) tyrosine phosphorylation (Jia and 
Wu 2007). Indeed, the incubation of the pancreatic INS1-E β-cells with 
MGO results in a glycogen synthase kinase (GSK3) mediated impairment 
of insulin secretion action (Maessen et al. 2015). In vivo, it has been 
demonstrated that MGO induces insulin resistance and salt sensitivity by 
increasing oxidative stress in Sprague–Dawley rats (Guo et al. 2009). In 
support of animal data and studies in animal models, a very recent human 
study in healthy overweight individuals demonstrates that with a diet low 
AGEs reduces the risk of T2DM by improving insulin sensitivity (De 
Courten et al. 2016). Insulin resistance is typically defined as decreased 
sensitivity or responsiveness to metabolic actions of insulin. However, 
diminished sensitivity to the vascular actions of insulin also plays an 
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important role in the pathophysiology of insulin-resistant states (Baron et al. 
1991, Natali et al. 1997). Indeed, endothelial insulin resistance is typically 
accompanied by reduced   phosphatidylinositol 3 kinase (PI3K)/NO 
pathway and an intact or heightened mitogen-activated protein kinase 
(MAPK)/ET-1 pathway. 
We have shown that MGO alters the sensitivity of the endothelium to insulin 
action both in vitro and in vivo. In particular, high levels of MGO cause an 
alteration in the release of two important vasoactive molecules by the 
endothelium: ET1 (vasoconstrictor action) and NO (vasodilatory action), 
highlighting MGO as an important culprit of endothelial dysfunction 
associated with insulin resistance (Nigro et al. 2014). Indeed, insulin 
resistant states are associated with metabolic abnormalities that include 
glucotoxicity, lipotoxicity and inflammation, thus contributing to the 
progression of long term endothelial dysfunction.  
 
6. Effect of MGO accumulation on vascular function 
 
In the last decades, several studies have been focused on the central role of 
MGO in vascular defects (Shamsaldeen et al 20016), particularly on 
endothelial dysfunction, which is considered an important factor in the 
development of cardiovascular disease (Fig. 4).   
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Figure 4. Sources of methylglyoxal (MGO) accumulation contributing to vascular 
dysfunction. Hyperglycemia, oxidative stress, inflammation and exogenous sources of 
MGO contribute both to the increase of MGO levels and the decrease of glyoxalase 1 (Glo1) 
activity. MGO-Glo1 imbalance leads to vascular dysfunction contributing to endothelial 
insulin-resistance, hypertension, atherosclerosis, microvascular complications, ageing and 
neuro-degeneration. (Nigro et al. 2017) 
 
Brouwers et al. (2010) have demonstrated that Glo1 overexpression 
improved diabetic-induced impairment of NO-mediated relaxation. In vivo, 
exogenous administration of MGO to rats induces diabetes-like 
microvascular changes (Berlanga et al. 2005) and the impairment of 
endothelial function (Sena et al. 2012). Moreover, recent studies have shown 
that methylglyoxal induce vascular dysfunction in rat aorta, mesenteric 
arterial bed (Thilavech et al. 2017) and causes vascular contractile 
dysfunction in spontaneously hypertensive rats (SHR) (Mukohda et al. 
2012). Dhar et al. have demonstrated a novel finding and a probable 
mechanism of increase in blood pressure, in particular they shown that MGO 
activates NF-κB through RAGE and thereby increases renin-angiotensin 
levels (Dhar et al. 2014). The MGO can impair the NO homeostasis and this 
has been related to endothelial dysfunction via a modulation of eNOS (Su et 
al 2013 and Turkseven et al 2014). Moreover, MGO and MGO-derived 
AGEs also play a harmful effect on microvascular function, contributing to 
the onset of nephropathy and neuropathy. Overexpression of Glo1 enzyme 
is important in the prevention of early renal impairment in rat models of 
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diabetes (Brouwers et al. 2014), but also independently of hyperglycemia in 
apo E-/- mice. This is also confirmed by the evidence that MGO 
accumulation in Wistar normal rats impairs several renal disease markers 
progressively observed in diabetic Goto-Kakizaki rats (GK) (Rodrigues et 
al. 2014). Based on these findings, it became clear that an effective reduction 
of MGO accumulation is crucial for preserving vascular function. 
 
7. Role of MGO in the development of vascular complications 
 
Hyperglycemia is a common feature in patients with diabetes mellitus 
(DM). DM is a common disease affecting more than 451 million people 
worldwide (Cho et al. 2018). One of the major concerns associated with 
diabetes relates to the development of micro-vascular (diabetic nephropathy, 
neuropathy, and retinopathy) and macro-vascular complication (coronary 
artery disease, peripheral arterial disease, and stroke), which greatly 
contribute to the high morbility and mortality associated with the disease 
(Fig. 5). 
 
7.1 Microvascular complications 
 
Results from both experimental and clinical studies on diabetes have 
demonstrated that hyperglycemia-induced MGO accumulation plays an 
important role in pathogenesis of microvascular complication.  
 
Nephropathy 
 
Diabetic nephropathy is the major cause of kidney disease and is a major 
risk factor for the development of macrovascular complications in patients 
effected by diabetic (Maessen et al. 2015).  Indeed, it has been demonstrated 
that in cultured cells and kidneys from diabetic mice, increased glycolytic 
flux causes methylglyoxal modifications of the corepressor mSin3A, 
resulting in enhanced angiopoietin-2 expression, sensitizing microvascular 
endothelial cells to the proinflammatory effects of tumor necrosis factor 
(TNF-α) (Yao et al. 2007). Moreover, experimental studies in renal cells 
demonstrated that the MGO-induced inactivation of mitochondrial 
respiratory, chain may play an important role in renal cellular toxicity and 
development of diabetic nephropathy (Rosca et al.2002, Maessen et al. 
2015). 
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Retinopathy 
 
Diabetic Retinopathy is a second common microvascular complication of 
DM, which causes serious damages in the retina, leading to increased 
vascular permeability, capillary microaneurysms, capillary degeneration 
and neovascularization (Forbes and Cooper 2013). Many clinical studies 
have demonstrated that, in both type 1 and type 2 diabetes (Fosmark et al. 
2009, Fosmark et al. 2006), increased serum levels of the specific MGO-
derived AGEs end product hydroimidazolone, is associated with the 
development of diabetic retinopathy (Fosmark et al. 2006). Moreover, 
overexpression of the Glo1 enzyme in diabetic rats prevents hyperglycemia-
induced formation of MGO-derived AGEs in the neural retina and protects 
against retinal capillary degeneration over 6 months of diabetes (Queisser et 
al. 2010, Berner et al. 2012). 
 
Neuropathy 
 
Diabetic neuropathy is the most common complication of DM affecting as 
many as 50% of patients with type 1 and type 2 DM. In most cases, it is 
associated with foot ulcers, gangrene and limb amputation (Costa and 
Soares 2013,  Chawla  et al. 2016). The risk of diabetic neuropathy 
development is directly proportional to both the duration and magnitude of 
hyperglycemia. Several studies have confirmed the role played by glycation 
in diabetic neuropathy, however only a few studies focused specially on the 
importance of MGO and Glo1 (Jack and Wright 2012). 
 
7.2 Macrovascular complications 
 
Atherosclerosis  
 
The atherosclerosis is a major cause of mortality in the people with diabetes 
(Grundy et al.1999). In most cases, the underlying process is a narrowing of 
arterial walls throughout the body (Maessen et al. 2015). In detail, it is a 
result from chronic inflammation and injury to the artery wall in the 
peripheral or coronary vascular system and of elevated levels of the low-
density lipoproteins (LDL). Many studies have demonstrated that LDL can 
be modified by MGO, resulting in a change in both their physiological and 
biological properties (Schalkwijk et al 1998, Rabbani and Thornalley 2011, 
Turk et al. 2011, Brown et al. 2005). LDL play a significant role in the 
Background 
 
 30 
enhancement, development and progression of atherosclerosis, through a 
pathway that involves endothelial cell dysfunction.  
 
Hypertension  
 
MGO has been demonstrated to be involved in the development of other 
different macrovascular disease, such as the hypertension, but the exact 
mechanism is not yet fully understood. A link between MGO accumulation 
and hypertension has been demonstrated in rats with increased MGO levels 
in aortic and renal tissue (Guo et al. 2009, Wu and Juurlink 2002, Wang et 
al. 2004, Chang et al. 2005). Rats treated with MGO in drinking water show 
the increase systolic blood pressure and higher plasma levels of aldosterone, 
renin and catecholamines (Dhar et al. 2014). Similarly, a diet high in 
fructose, precursor of MGO, induces hypertension and renal injury in rats 
(Guo et al. 2012, Sánchez-Lozada et al. 2007). Although a dose of 1% MGO 
in drinking water alone has no effect on blood pressure for up to 4 weeks in 
Sprague-Dawley rats (Vasdev et al. 1998), surprisingly enough the same 
dose in combination with high-salt diet induced hypertension and enhances 
renal oxidative stress (Guo at al. 2009), suggesting that MGO causes 
hypertension only in rats with enhanced renal oxidative stress (Maessen et 
al.2015). Moreover, other studies showed that a significant increase in blood 
pressure coincided with elevated MGO levels in plasma and aorta of SHR 
in an age-dependent fashion, compared with age-matched Wistar–Kyoto 
rats (WKY) (Wang et al.2004, Wang et al. 2005). In the last few years, 
different mechanisms have been suggested as link between MGO and 
hypertension, as such it is known that MGO causes vascular Ca 2+ channel 
alterations, leading to increased cytosolic [Ca2+], peripheral vascular 
resistance and hypertension (Vasdev et al. 1998). Moreover, another study 
demonstrated that MGO-induced hypertension takes palace via angiotensin 
II type 1 receptor-mediates pathway (Chen et al. 2013). An improvement in 
blood pressure has been observed in SHR after treatment with 
aminoguanidine, a known scavenger of MGO (Wang et al. 2007, Wang et 
al. 2008). 
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Figure 5. Major microvascular and macrovascular complications associated with 
diabetes mellitus. doi: 10.2210/rcsb_pdb/GH/DM/monitoring/complications 
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Effect of glyoxalase 1 gene deletion on glucose homeostasis and 
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1.1 Risk factors for the development of complications in DM 
Beyond the classification of DM, the presence of chronically elevated blood 
glucose levels is implicated in the progression of diabetes complications. 
For this reason, the primary goal of therapeutic treatment is to reduce 
hyperglycemia. Nonetheless, while most of the literature claims the benefits 
of glycemic control in the prevention of vascular complications (Cefalu 
2006), additional evidence suggests that the risk of complications may be 
decreased further if glycated hemoglobin (HbA1c) is reduced below levels 
currently accepted as clinical goal (Stratton et al. 2000). In support of this 
possibility, Khaw et al (2001) demonstrated that a reduced HbA1c level is 
associated with a lower rate of cardiovascular disease, even in non-diabetic 
subjects. At the same time a clinical study on HbA1c contribution to 
retinopathy in type 1 diabetic patients shows that lowering HbA1c levels is 
not enough to prevent the increased incidence of events in the long term 
(Lind et al. 2010). Moreover, it is known that as blood pressure levels 
increase in diabetics there is a parallel increase in cardiovascular disease, 
diabetic retinopathy and nephropathy (Rask-Madsen and King et al. 2013). 
Many studies have demonstrated clear benefits in lowering blood pressure. 
Indeed, in the UKPDS trial, tight blood pressure control with angiotensin-
converting enzyme (ACE) inhibitors or -blockers significantly reduced 
diabetes-related events and diabetes-related deaths (U.K Prospective 
Diabetes Study Group 1998, Katherine L Bate and George Jerums 2003). In 
addition, other studies demonstrated that it is important to control also the 
levels of dyslipidemia to reduce the risk of development of diabetic 
complications. Indeed, two placebo-controlled trials have shown that 
treatment with statins reduces the risk of a major cardiovascular event by 
37% in patients with type 2 diabetes without clinically apparent 
cardiovascular disease (Heart Protection Study Collaborative Group. 2002, 
Colhoun et al. 2004, Marshall and Flyvbjerg 2006).  A recent study found 
that the risk of diabetic complication can be reduced through a multifactorial 
approach, for example reducing the smoke or administration the low-dose 
of aspirin (Marshall and Flyvbjerg 2006). Therefore, all these studies 
suggest that other risk factors besides poor glycaemia control may be 
important for the onset of vascular complications (Bots et al. 2016). 
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1.2 Rodent Models of DM and its related complications 
Studies in animal models have provided significant advances to the 
knowledge of cardiovascular complications in understanding to which 
extent insulin resistance, hyperinsulinemia and hyperglycemia may 
individually contribute to vascular and cardiac dysfunction in diabetes. 
Among the commonly used models, the ob/ob mouse is a diabetic animal 
with genetic mutations on the leptin gene. As a consequence of this defect, 
ob/ob mice develop hyperphagia and obesity, reduced glucose tolerance, 
severe hyperinsulinemia, insulin resistance and impaired would healing 
(Potenza et al. 2011). The db/db mice, carrying a mutation on the gene 
encoding for the leptin receptor in C57b/KsJ strain, show hyperphagia, 
obesity and early insulin resistance. This model rapidly develop 
hyperglycemia, diabetic nephropathy and ketosis as their β-cells are unable 
to maintain high levels of insulin secretion required for survival (Maessen 
et al. 2015). 
In addition, several diabetic models have been utilized to understand the 
relationship between metabolic control and cardiovascular health. eNOS 
KO/lepr (db/db) double knockout (DKO) mice develop obesity, 
hyperglycemia and also hypertension (Potenza et al. 2011). The cp-cp 
(ceruloplasmin) rats spontaneously develop the pathophysiological 
characteristic resembling the human metabolic syndrome, for this reason are 
use as model of diabetes. In detail the cp/cp rats are homozygous for 
autosomal recessive cp gene and develop atherosclerosis, ischemic 
myocardial lesions and microvascular renal dysfunction not accompanied 
by hypertension (Russell et al. 1998). The GK rats show neonatal β-cell 
mass deficiency, which is responsible for the basal hyperglycemia. Indeed, 
at 8 weeks of age, sustained hyperglycemia is accompanied by both severely 
impaired insulin release and insulin resistance (Miralles and Portha 2001). 
This animal model exhibits endothelial dysfunction as early as 4 months of 
age and has provided important informations on the relationship between 
changes in β cells mass and the occurrence of diabetic vascular 
complications.  
Moreover, also the Zucker Diabetic Fatty (ZDF) rats, selectively inbred for 
hyperglycemia, can be placed in this category. Indeed, at 10 weeks of age, 
ZDF rats show more than a 4-fold increase in blood glucose levels that 
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remain high throughout their entire lifespan. They show coronary and aortic 
endothelial dysfunction that are involved in atherogenesis and vascular 
alterations occurring in this model (Otlam et al. 2008, Chinen et al. 2007).  
SHR rapresent a genetic model of hypertension, in which the defects in 
endothelial insulin signalling with impaired PI3-Kinase-dependent and 
augmented MAPK-dependent activities precede several disturbances of the 
metabolic syndrome (Potenza et al. 2005). For this reason, they are used in 
the studies of endothelial function.  
Further rodent models have been generated to study the role of insulin-
signalling mediators in the pathogenesis of DM. In detail, the deletion of 
IRS-1 in the IRSKO mouse (IRS-1 KO) leads to β-cell hyperplasia and 
insulin resistance, mainly localized to skeletal muscle tissue. Hypertension 
onset, secondary to impaired endothelium-dependent relaxation, and 
hypertriglyceridemia development, secondary to impaired activation of 
lipoprotein lipase in insulin resistant adipose tissue, have been observed in 
these mice. Akt2 knockout in mice results in glucose intolerance, 
hyperinsulinemia, insulin resistance and, under some conditions, overt 
diabetes. Akt 2 is predominantly expressed in pancreatic β-cells, skeletal 
muscle and brawn fat, but also in platelets. Indeed, Akt2 knockout mice (Akt 
2 KO) display defects in platelet aggregation and thrombus formation 
(Woulfe et al. 2004). Moreover, liver-specific insulin receptor knockout 
(LIRKO) mice exhibit a dramatic elevation in blood glucose and the loss of 
gluconeogenesis regulation. It has been demonstrated that LIRKO mice 
show marked hypercholesterolemia and develop severe atherosclerosis at 12 
weeks, when fed with atherogenic diet (Biddinger et al. 2011). 
In the absence of appropriate diabetic/atherosclerotic models, exposure to 
chemicals (e.g streptozotocin) as well as to diabetogenic or atherogenic diets 
has been used to evaluate the impact of hyperglycemia, obesity, insulin 
resistance and hypercholesterolemia on vascular complication development 
in wild type and genetically modified rodents (Potenza et al. 2011). Schreyer 
et al. have demonstrated the atherogenic diet containing 1.25% cholesterol, 
15% fat, and 0.5% cholic acid induces atherosclerosis. Moreover, also a 
diabetogenic diet containing 35.5% fat (58% of calories, primarily lard) and 
36.6% carbohydrate (primarily sucrose)) may induce vascular lesions by 
altering both lipid and glucose metabolism, while a high fat/high sucrose 
diet used to induce obesity and diabetes in C57BL/6 mice, may provide an 
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important tool for the study of diabetes accelerated atherosclerosis (Schreyer 
et al. 1998). In rats the administration of streptozotocin (STZ), after a 
primary administration of nicotinamide adenine dinucleotide (NAD), 
produces a T2DM model at a rate of 75-80%, which develops a mild and 
stable hyperglycemia without changes in plasma insulin (Masiello P. et al. 
1998). Combination of STZ administration in animals with a genetic insulin 
resistant background (e.g. in ZFR model) or under a high fat or high fructose 
diet produces models that develop overt hyperglycemia in the presence of 
normal blood insulin and, hence, are regarded as more appropriate for 
T2DM studies (Chatzigeorgiou et al. 2009). Moreover, other studies have 
shown that the long-term administration of diets containing front 40% to 
60% of lipids promotes metabolic disorders in animal models (Flanagan et 
al., 2008); and induces adipocyte hypertrophy (Barbosa-da-Silva et al. 
2012), T2DM, hypertriglyceridemia (Fraulob et al. 2010) and liver steatosis 
in mice (Aguila et al. 2003, Barbosa-da-Silva et al. 2013). 
Therefore, the use of the appropriate animal models can provide interesting 
data needed to clarify the pathophysiological mechanisms responsible for 
the onset of diabetic complications. 
 
1.2.1 Mouse models of MGO accumulation 
To prove the effect of MGO on vascular function, animal models that allow 
to observe the systemic implications of an imbalanced 
accumulation/detoxification ratio of MGO have been generated. Among 
these, the chronic administration of a MGO solution has been performed in 
rodents in many studies. Dhar et al (2011) have been demonstrated that 
chronic MGO infusion by minipumps causes pancreatic β-cell dysfunction 
and induces DM in Sprague-Dawley rats. Others have been demonstrated 
that high MGO levels induce vascular contractile dysfunction in arterial wall 
of SHR (Mukohda et al. 2012). We have previously demonstrated that 
intraperitoneal administration of MGO to C57BL/6 mice impairs whole-
body insulin sensitivity and induced endothelial insulin resistance (Nigro et 
al. 2014). However, it is important to note that exogenous sources of MGO 
are only partially absorbed and not completely accumulated in tissues as free 
MGO, thus limiting the interpretation of these studies. The measurement of 
tissue and plasma levels of MGO in experimental models is, therefore, 
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necessary to ensure the patho-physiological relevance of the animal models. 
To bypass these limitations, a possibility is to modulate Glo1 activity and/or 
its expression. Indeed, MGO accumulation may be induced by reducing 
Glo1 activity, through the chemical Glo1 inhibitor “SpBrBzGSHCp2” or 
silencing Glo1 expression (Nigro et al. 2017). Interestingly, it has been 
shown that non-diabetic mice knock-down for Glo1 (Glo1 KD) expression 
show an increase of MGO modified proteins and oxidative stress, causing 
alteration in kidney indistinguishable from those caused by diabetes (Giacco 
et al. 2014). Bierhaus et al (2012) demonstrated that this mouse model 
develops the thermal and medical hyperalgesia, signs of peripheral 
neuropathy. Moreover, the beneficial effect of MGO detoxification have 
been proved by studies using Glo1 overexpressing models. Interestingly, 
Glo1 over-expression in STZ-induced diabetic mice prevents diabetes-
induced oxidative stress and the development of kidney pathology, despite 
unchanged levels of diabetic hyperglycemia (Giacco et al. 2014).  Moreover, 
Glo1 overexpression ameliorates renal ischemia-reperfusion injury 
(Kumagai et al. 2009), reduces endothelial dysfunction and attenuates early 
renal impairment in rat model of diabetes (Brouwers et al. 2014).  
This is in line with a recent clinical study reporting that pharmacological 
induction of Glo1 activity improves insulin sensitivity and glycemic control 
in obese patients (Xue et al. 2016). Furthermore, Glo1 has been linked to 
coronary artery disease (Makinen et al. 2014) and hypertension (Wilson et 
al. 1991) in epidemiological studies. A recent study obtained in Glo1-tg 
mice has shown that Glo1 overexpression is able to prevent the MGO-
mediate increase of inflammation in diabetes, which leads to endothelial cell 
loss and, contributes to the development of diabetic cardiomyopathy 
(Vulesevic et al. 2016). Moreover, the overexpression of Glo1 reduces age-
related glycative and oxidative stress in the vasculature and attenuates 
endothelial dysfunction through the modulation of eNOS phosphorylation 
from early aging. This proves that the regulation of glycative stress by 
enhanced Glo 1 activity counteracts physiological vascular aging. 
Therefore, the regulation of glycative stress may represent a versatile target 
for the prevention of vascular aging and its associated complications (Jo-
Watanabe et al. 2014, Nigro et al. 2017). 
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1.3 Aim 
 
DM is a common metabolic disorder that is strongly associated with vascular 
complications. Several studies demonstrated that diabetes is linked to 
macro- and microvascular complications, which are responsible for high 
mortality and morbidity of the disease. For this reason, it is considered an 
important public health problem. 
Hyperglycemia represents the main feature of DM and one of the major 
cause of plasma and intracellular MGO accumulation. In physiological 
conditions, MGO is efficiently detoxified by the glyoxalase system, 
however its levels increase under pathological conditions, such as 
hyperglycemia contributing to cardiovascular complication associated with 
diabetes.  Indeed, several studies carried out in models of hyperglycemia 
have proved the toxic effect of MGO and its derived AGEs on micro and 
macrovascular function (Chinen et al. 2013), on insulin sensitivity of 
muscle, adipose tissue and β-cells.  However, the specific effect of a 
physiological accumulation of the MGO a tissue damage has not been yet 
clarified. To this aim, it is necessary to use an optimal experimental model 
to investigate the pathological processes by which MGO favors the onset of 
DM and its associated complication. 
This work aims to investigate the impact of endogenous MGO accumulation 
on metabolic and vascular functions in Glo1-knockdown mice (Glo1KD).  
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1.4 Results 
1.4.1 Metabolic characterization of Glo1KD mice 
Glo1KD mice and their wild type littermates (WT mice) were used to 
evaluate the effect of MGO accumulation on glucose tolerance. In order to 
validate  this experimental model, the first step was to evalaute the Glo1 
expression in different tissues by Real Time-PCR. As expected, Glo1KD 
mice show a significant reduction in tissue expression of the Glo1 gene 
compared to WT mice (Figure 1.1A). In detail, the absolute quantification 
revealed that  Glo1KD  mRNA levels are reduced from 30% to 50% in 
vascular tissue, skeletral muscle and adipose tissue isolated from Glo1KD 
mice compared to WT mice. To test if the partial deletion of Glo1 expression 
was enough to induce MGO accumulation, endogenous MGO levels were 
measuread by HPLC and resulted to be increased by 1.5-fold in the serum 
from Glo1 KD mice compared to WT mice (figure 1.1 b). 
 
 
Figure 1.1 Expression levels of the Glo1 gene and serum MGO concentration. (a) The 
expression of Glo1 gene was measured in aorta, muscle (quadriceps) and adipose tissue 
(epididymal fat) of Glo1KD and WT mice. Glo1 expression was normalized on the number 
of GAPDH molecules, used as a housekeeping gene. (b) Serum MGO concentrations were 
measured by HPLC. Statistical analysis was performed by Student t-test, where p≤0.05 was 
considered statistically significant (*** p≤0.001). 
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Metabolic characterization of Glo1KD mice have been evaluated during 
lifespan. As shown in table 1.1, the data obtained indicate that Glo1KD mice 
show no significant variation in body weight, food intake, fasting and fed 
glycaemia neither at 5 nor at 10 months of age, indicating that Glo1KD mice 
are normoglycemic and, thus, do not display a diabetic phenotype. Glucose 
levels have been measured during intraperitoneal Glucose Tolerance Tests 
(ipGTT) in order to evaluate the ability of the mouse to restore glucose levels 
at normal values after a bolus of glucose. 
 
 
Table 1.1. Metabolic parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 months 
 
 10 months 
Variable WT mice Glo1KD mice Test T WT mice Glo1KD 
mice 
Test-T 
Body 
weight 
(g) 
25.4±0.8 24.5±0.7 n.s. 32.6±1.5 35.1±1.8 n.s. 
Fold 
intake 
2.99±0.04 2.9±0.13 n.s        -      - n.s 
Fasting 
glycaemi
a (mg/dl) 
105.9±5.3 97.1±3.5 n.s. 114.6±8.4 106.4±6.0 n.s 
Fed 
glycaemi
a 
(mg/dl) 
138.9±4.1 145.6±6.9 n.s. 143.6±3.1 137.3±4.4 n.s. 
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Figure 1.2 Glucose Tolerance Test (ipGTT). (a, c) The graph shows the curves related to 
blood glucose levels of WT mice and GloKD mice within 2 hours after intraperitoneal 
administration of a glucose bolus (2 g / kg) at 5 and 10 months. Blood glucose was 
measured by the use of a portable blood glucometer at the indicated times. (b, d) The bars 
of the graph analyze the area under the glucose curve of Glo1KD and WT mice. Statistical 
analysis was performed by Student's t-test (* p≤0.05; ** p≤0.01; *** p≤0.001). 
 
 
No differences in glucose tolerance have been revealed at 5 months of age. 
By contrast, Glo1KD mice develop a reduced glucose tolerance at 10 months 
of age, compared to WT mice. This is indicated by both the calculation of 
the area under curve (WT 12990±1595 vs KD 23944±2300) and by the 
single time points of glucose measurements performed during the entire test, 
when from 15 to 120 minutes following glucose bolus, blood glucose levels 
are higher in Glo1 KD mice compared to WT mice (figure 1.2 c).  
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Figure 1.3 Insulin tolerance test (ipITT) 
(a) The graph shows the curves related to blood glucose levels of WT mice and GloKD 
mice within 2 hours after intraperitoneal administration of a insulin (0,75 U/kg). Blood 
glucose was measured by the use of a portable blood glucometer at the indicated times. 
(b) The bars of the graph analyze the area under the glucose curve of Glo1KD and WT 
mice. Statistical analysis was performed by Student's t-test (* p≤0.05; ** p≤0.01; *** 
p≤0.001). 
 
Next, insulin sensitivity has been evaluated by means of the insulin 
tolerance test (ITT). The data obtained show that insulin sensitivity is not 
affected in Glo1KD mice compared to WT mice (figure 1.3). In light of the 
impairment of glucose tolerance pancreatic function has been tested by 
glucose-stimulated insulin secretion (GSIS). 
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Figure 1.4 Glucose-stimulated insulin secretion (GSIS) and fasting insulinemia (A) The 
graph shows the fasting insulinemia values at 3 minutes and 5 minutes after administration 
of an intraperitoneal glucose (3 g / kg) in Glo1KD and WT mice. Insulin values were 
measured in serum by RIA test. (B) The bars in the graph represent the calculation of the 
area under the curve of my insulin values obtained during the insulin secretion test. 
Statistical analysis was performed by Student's t-test (Glo1KD vs WT mice: * p ≤0.05; ** 
p≤0.01; 3 and 30 minutes vs. time 0: #p≤0.05; # #p≤0.01) 
 
 
The insulin plasma levels have been measured in the fasted state and after 3 
and 30 minutes following glucose administration (3 g / kg). As shown in the 
panel a, the Glo1KD mice have a higher fasting insulinema (KD 0.69±0.18 
VS 0.28±0.05 WT) with a reduction in insulin secretion in response to 
glucose compared to WT mice. Panel b shows the values of the area under 
the curves of insulinemia levels measured during the GISIS test. 
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1.4.2 Vascular function of Glo1KD mice 
 
Another objective of this study was to investigate the effect of the inhibition 
of Glo1 on vascular function of Glo1KD mice and, therefore, on the 
development of complications associated with diabetes.  
Systolic blood pressure was measured during lifespan (at 5, 10 and 15 
months of age) and the recorded data show that it is higher in Glo 1KD mice 
compared to WT mice (figure 1.5), already at 5 months of age, anticipating 
the physiological increase in blood pressure ad observed in WT mice at the 
age of 15 months. 
 
 
 
 
Figure 1.5. Measurement of systolic blood pressure. Systolic blood pressure is measured 
in Glo1KD and WT mice by the method CODA. Systolic blood pressure is expressed in 
mmHg. Statistical analysis was performed using the t-Student * p ≤0.5 and ** p≤0.01 test 
 
 
As determination factor in raising blood pressure, vascular resistance was 
also evaluated. To this aim, the vasodilatory response to increasing 
concentration of acetylcholine was measured ex vivo in the aortae isolated 
from WT and Glo1KD mice. As shown in the figure 1., the percentage of 
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residual vasoconstriction, used as a measure of vessel vasodilation, is 
significantly higher in Glo1KD mice compared to WT mice at 10 months of 
age. Preliminary data indicate that an impaired endothelial-dependent 
vasodilation is already observed at 5 months of age in Glo1KD mice, while 
the same values of residual vasoconstriction is reached by the 2 groups of 
mice at 18 months (data not shown), suggesting that Glo1 KD mice anticipate 
an impairment of vasodilation which is physiologically developed by WT 
mice with age. 
 
 
 
Figure 1.6. Measurement of endothelium-dependent vasodilation. The % of residual 
vasoconstriction after vasoconstrictive stimulation (phenylpinephrine) was measured by 
the detection of vascular tension following stimulation with increasing concentrations of 
the acetylcholine vasodilator. Statistical analysis was performed using the t-Student * p 
≤0.5 and ** p≤0.01 test 
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1.5 Discussion 
 
It is known that MGO is increased from 2 to 5- fold in diabetic patients as a 
consequence of the imbalance between the generation of/exposure to MGO 
and the impaired activity of its detoxification enzyme, specifically the 
glyoxalase system (Rabbani and Thornelly 2016). Indeed, MGO 
accumulation may be the result of the reduced expression or activity of the 
rate limiting enzyme Glo1 (Maessen et al. 2015). Several studies have 
demonstrated an association between high MGO and its derived AGEs 
levels and the increased risk of micro and macrovascular complications 
(Bourajjai et al 2003). Moreover, a GWAS study identified the decreased 
Glo1 expression as a driver of coronary artery disease (Makinen et al. 2014). 
Although chronic hyperglycemia seems to be the leading cause of MGO 
accumulation, it has also been demonstrated that reducing HbA1c to normal 
levels, in diabetic patients is not sufficient to prevent the onset of vascular 
events (Lind et al. 2010), suggesting that hyperglycemia itself is not the only 
driver of tissue dysfunction and complications progression in diabetes. 
Moreover, even if normalized on glucose levels, intracellular MGO is higher 
in diabetic patients (Fleming et al. 2012). Therefore, despite the progress 
made in the recent years in this field, further research is needed to pinpoint 
the role played by MGO in the development and progression of DM. To this 
aim, a promising contribution may be provided by the use of experimental 
models accumulating MGO. Our previous studies demonstrated that MGO 
impairs insulin sensitivity by changing the balance of NO and ET-1 release 
(Nigro 2014). In the chapter 2 of this thesis I have reported our new data 
showing that MGO induced down-regulation of miR-190a and miR-214 
plays a role in endothelial insulin resistance (Mirra et al 2017, Nigro et al. 
2018). In this part of the study, we sought to investigate the effect of MGO 
on glucose homeostasis and vascular function in vivo, by the use of a mouse 
model with a partial deletion of Glo1 gene. The partial reduction of Glo1 
expression is associated to 1.5-fold increased levels of MGO in Glo1KD 
mice. The intracellular accumulation of MGO has been demonstrated by our 
previous work in Glo1KD MAECs (Nigro et al. 2018) and by Morgenstern et 
al. in murine Schwann cells (Glo1KO) (2016). In line with data obtained by 
Wortman et al. (2016) in Glo1KD mice, we have not observed significant 
variation in body weight and food intake. Moreover, fasting and random-fed 
glycemia in Glo1KD mice is not higher than in WT littermates. Nevertheless, 
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a glucose intolerance has developed by Glo1KD mice at 10 months. These 
results suggest the possibility that a reduced insulin sensitivity of target 
tissues, or an insufficient production of insulin after glucose loading, could 
be responsible for the phenotype observed. Indeed, data in literature 
demonstrate that hyperglycemia- dependent MGO accumulation in GK rats 
associate with peripheral insulin resistance and impaired insulin secretion 
(Matafone et al. 2011). However, Glo1KD mice do not show systemic insulin 
resistance as indicated by ITT performed both at 5 and 10 months of age. 
Conversely, they are characterized by an impaired glucose-stimulated 
insulin secretion with a basal hyperinsulinemia, compared to WT mice. This 
important finding is in line with previous research performed by our group 
demonstrating how MGO impairs GISIS in both INS1-E cells and isolated 
islets from mice (Fiory et al. 2011). All these data demonstrate for the first 
time that Glo1KD mice develop an age-dependent glucose intolerance, in the 
absence of fasting hyperglycemia, and suggest that this is dependent on the 
impairment of β-cell function, rather than a peripheral insulin resistance.  
Marow et al. (2018) have very recently demonstrated that the elevation of 
MGO levels due to Glo1KO in Drosophila induces obesity and 
hyperglycemia. We show here for the first time in a mammalian model that 
the partial impairment of MGO detoxification system is enough to 
recapitulate several of the metabolic phenotypes associated to T2DM. We 
and others have previously provided evidence that MGO accumulation and 
its derived adducts favor the onset of vascular complications (i.e 
nephropathy and peripheral neuropathy) in Glo1KD mice and endothelial 
dysfunction in vitro (Nigro et al. 2014, Nigro et al. 2018). As two mutually 
related processes in the development of diabetes, together with glucose 
homeostasis, the hemodynamic function was evaluated in Glo1KD mice, to 
test the specific contribution of MGO accumulation to the pathogenesis of 
the diabetes. Therefore, we investigated the effect of Glo1 inhibition on 
blood pressure, that is known to be increased in the rats with high MGO 
levels (Wang et al.2006, Maessen et al. 2015). The results show that Glo1KD 
Glo1 down regulation is sufficient to increase pressure in Glo1KD mice and 
also to impairs the endothelium-dependent vasodilation. Our hypothesis is 
that the latter may be the cause of peripheral vascular resistance leading to 
the increase in blood pressure. Moreover, Giacco et al. (2014) have 
demonstrated that early signs of kidney damage occur early in life of Glo1KD 
mice. Differently from our evidence, these signs of nephropathy are not 
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accompanied by an increase in blood pressure in this paper (Giacco et al. 
2014) However, it is important to note that blood pressure was recorded in 
a much lower age (8week) than in our work (5 months), therefore more than 
in 2 months of age are necessary, before hypertension is clinical evident in 
Glo1KD mice. 
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1.6 Conclusion  
 
The data obtained by this study demonstrate that simply elevating the 
endogenous MGO levels, which could be due to either evaluated MGO 
production detoxification, could be the cause of many of the metabolic 
phenotypes observed in diabetic patients. This evidence places MGO not 
only downstream the impairment of the glucose metabolism, but also 
upstream of both glucose and vascular homeostasis, in term of the chain of 
causality. Therefore, the Glo1KD mouse appears to be a novel and good 
model for further investigations on the pathogenesis of DM and the 
development of novel pharmacological interventions to counteract diabetes 
complications. 
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1.7 Material and Methods 
 
Mice 
 
Glo1 knockdown mice (Glo 1 KD) were generated and characterized as 
previously described (Queisser et al. 2010, Bierhaus et al. 2012, Giacco et 
al. 2014). Mice were housed in a temperature-controlled (22 °C) room with 
a 12 h light/dark cycle, in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the National Institutes of Health 
(publication no. 85-23, revised 1996), and experiments were approved by 
the ethics committee of the MIUR.  
 
Measurement of MGO 
 
MGO concentration was measured in the serum of WT and Glo1KD mice 
by HPLC after derivatization with 1,2-diamino-4,5-dimethoxybenzene as 
previously described (McLellan et al.1992). 
 
Measurement of blood pressure by tail cuff methods 
 
The blood pressure evaluation was performed using the tail-cuff system 
using the CODA 8-Channel High Throughput instrument. This system 
allows a non-invasive measurement of blood pressure in mice. The tail-cuff 
system uses the Volume Pressure Registration (VPR) to measure blood 
pressure by determining the volume of blood flowing into the tail. The 
animals, taken from the base of the tail, were placed in the restrainer. 
Subsequently, the tail that emerges from the restrainer has been connected 
to the tail-cuff and the VPR detection system for recording the blood 
pressure values. During the measurement, the body temperature of the 
animals was constantly monitored by infrared thermometer. 
 
Reverse transcription and Real Time-PCR 
 
RNA was isolated from aorta, skeletal muscle and adipose tissues using 
miRNeasy mini kit (QIAGEN) according to the manufacture’s instructions. 
Reverse transcription of 1 μg of total RNA was performed using Super 
Script III (Life Technologies, Carlsbad, CA, USA), according to the 
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manufacturer's instructions. Quantitative real-time PCR was performed in 
triplicate by using iQ SYBR Green Super mix on iCycler Real-Time 
Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The 
GAPDH gene was used as internal control and the results of Real time 
analysis are expressed as the ratio between the copy number variation 
(CNV) of Glo1 and that of the reference gene. Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to design 
primers specific, which were then purchased from Sigma-Aldrich (St Louis, 
MO, USA). Primers used for real-time Real-time-PCR are as follow:                   
 
GAPDH                
 
Forward 5’-AAGGCGGGGGCCCACTTGAA-3’ 
 Reverse 5’-TGGGTGGCAGTGATGGCATGG-3’ 
Glo1                       Forward 5’-CCCTCGTGGATTTGGTCACA-3′ 
                                     
 
 Reverse 5′-AGCCGTCAGGGTCTTGAATG-3′ 
 
Glucose tolerance test (GTT) 
 
Mice were fasted overnight. Glucose levels were determined at 0, 15, 30, 
45, 60, 90, 120 min after the administration of a 20% w/vol D-glucose 
solution (2g/kg body weight) by intraperitoneal injection. Blood was 
obtained from the tail vein. Blood glucose was assessed using a the 
glucometer One Touch® Ultra Lifescan (Johnson & Johnson, Milpitas, 
Italy).  
 
Insulin tolerance test (ITT) 
 
Mice were fasted for 4 h, then they are injected with insulin. The human 
insulin used WAS injected at the concentration of 0.25 UI/kg (Actrapid®, 
Novo Nordisk, Boulogne-Billancourt, France). Blood samples were taken 
from mice tail and glycaemia was analyzed by using a glucose analyzer 
(LifeScan). Glucose levels were determined at the following time points: 0, 
15, 30, 45, 60, 90, 120 min after insulin injection. 
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Glucose-Stimulated Insulin Secretion (GSIS) 
 
Animals were intraperitoneally injected with 3g/kg body weight of glucose. 
In parallel, blood samples were taken from mice tail, to assess glycaemia, 
and from orbital sinus in order to collect large volumes of blood to further 
measure serum insulin. Blood samples were collected 0, 3, 30 min after 
glucose injection. Blood samples were centrifuged at 1500 rpm for 20 min 
at room temperature and serum collected. Insulin levels were measured with 
radioimmunoassay (RIA) kit (#RI-13K, Millipore), according to the 
manufacturer’s protocol. 
 
Statistic Procedures 
 
Data are expressed as means ± SD, as indicated in figure legends. 
Comparison between groups was performed using Student’s t-test. A p-
value of less than 0.05 was considered statistically significant. 
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The role of miRNAs in MGO-induced insulin resistance in 
mouse aortic endothelial cells 
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2.1 Insulin action 
 
Insulin is a hormone which plays a key role in the regulation of blood 
glucose levels and in the carbohydrate and lipid metabolism, and it has 
significant influences on protein and mineral metabolism.  The effects of 
insulin on glucose metabolism vary depending on the target tissue. In 
particular, insulin inhibits gluconeogenesis and glycogenolysis and 
promoting the glycolysis and glycogenesis. Moreover, insulin stimulates the 
uptake and incorporation of amino acids into proteins, inhibits protein 
degradation, stimulates lipogenesis, and suppresses lipolysis (Qaid and 
Abdelrahman 2016). Insulin exerts its action by binding to its receptor (IR), 
a transmembrane glycoprotein with intrinsic protein tyrosine kinase activity. 
This receptor consists of an α-subunit, which binds the hormone, and a β-
subunit, which is a tyrosine protein kinase.  
Once activated, the receptor triggers a complex intracellular signalling 
network. IRS-1 binds PI3K that causes phosphorylation of the 3'OH on 
phosphatidyl inositol (PI) in the inner leaflet of the membrane to form PI (3) 
P. PI3K is a heterodimeric molecule composed of a regulatory (p85) and a 
catalytic subunit (p110).  It is known that targeted deletion of the PI3K 
regulatory subunit in mice results in increased insulin sensitivity. 
Conversely, gene knockout of the catalytic subunit results in insulin 
resistance and glucose intolerance (Chang et al. 2004). In absence of insulin 
stimulation, the p110 subunit is constrained and inhibited by the p85 
adaptive subunit; when appropriate cell stimuli are present, the catalytic 
subunit p110 of PI3K phosphorylates the PI (4,5) P2 molecule 
(phosphatidyl-inositol (4,5) bisphosphate), leading to the formation of PI 
(3,4,5) P3. In turn, PI (3,4,5) P3 active the AKT molecule (also known as 
protein kinase B or PKB) and is recruited from the plasma membrane. This 
lipid is very important because serve as plasma membrane docking sites for 
proteins that harbor pleckstrin-homology (PH) domains, including AKT and 
phosphoinositide-dependent kinase 1 (PDK1). The latter phosphorylates and 
activates Akt (Alessi et al. 1997). Akt has a pivotal role in the transmission 
of the insulin signal, by phosphorylating the enzyme GSK3, the forkhead 
transcription factors and cAMP response element-binding protein. As is the 
case for other growth factors insulin stimulates the extracellular signal-
regulated kinases/mitogen-activated protein Kinases (ERK/MAPK) 
pathway. This pathway involves the tyrosine phosphorylation of IRS 
proteins and/or Shc, which in turn interact with the adapter protein Grb2. 
Grb2 constitutively associates with Sos, the guanine nucleotide exchange 
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factor for plasma membrane–bound Ras. Docking of Grb2 to IRS proteins 
recruits Sos to Ras, resulting in the activation of its GTPase. This leads to 
the subsequent activation of the serine/threonine kinase cascade known as 
the MAPK cascade. This cascade relays the signal from the plasma 
membrane to the nucleus and is the essential signalling pathway for 
mitogenesis (Virkamäki et al. 1999). It has recently become evident that 
insulin also acts on endothelium where, through the activation of its own 
receptor, regulates the vascular tone (Scherrer et al. 1994). 
 
2.2 Insulin action on endothelium  
 
In the last years, endothelium is a considerate a new target of insulin action. 
One of the key vascular actions of insulin is to modulate vascular tone. To 
carry out its functions, the endothelium promotes the release of the 
vasodilator NO and the vasoconstrictor ET-1 (Sandoo et al. 2010). Insulin 
binding to its receptor on the endothelial cells activates the insulin receptor 
substrates: IRS-1 and IRS-2, thereby activating two different branches of 
insulin signalling. On one side, insulin binding to its receptor results in 
phosphorylation of insulin receptor substrate IRS-1, which then binds and 
activates PI3K, leading to phosphorylation and activation of PDK-1 via 
increases in PI (3,4,5)3P. PDK-1, in turn, phosphorylates and activates Akt, 
which then directly phosphorylates endothelial eNOS at Ser1177, resulting 
in increased eNOS activity and subsequent NO production (Muniyappa  et 
al. 2007). The eNOS dimer generates NO by means of the conversion of 
arginine in(to) NO and L-cytrulline by a ratio of 1 to 1. This is an oxygen 
and NADPH-dependent reaction.  eNOS is a central regulator of cellular 
function that is important to maintain endothelial homeostasis. On the other 
side, through the activation of IRS-2, insulin activates the proatherogenic 
Ras-Raf-MAPK pathway, resulting in secretion on ET-1. 
Insulin action in EC maintain the balance between the production of the 
vasodilator NO and the vasoconstrictor ET-1, with vasodilatation 
representing the normal response and impaired vasodilatation, or even net 
vasoconstriction, representing the abnormal responses associated with 
endothelial dysfunction (Eringa et al. 2004). We have recently demonstrated 
that MGO induces endothelial insulin-sensitivity by impairing the insulin-
mediated activation of PI3K/Akt/eNOS pathway and increasing the 
phosphorylation of Extracellular Signal-Regulated Kinase 1/2 (ERK 1/2). 
On the others side, thus leading to an imbalance between the production of 
NO and ET-1 by MAECs (NIGRO et al. 2014). 
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2.3 Biogenesis of miRNAs 
 
MicroRNAs (miRNAs) are small (20–22 nucleotides), non-coding RNAs, 
characterized by an evolutionary conservation and able to regulate gene 
expression at the posttranscriptional level. In more detail, the miRNA seed 
region interacts with the complementary sequence in at 3′ untranslated 
region (UTR) of target messenger RNAs (mRNAs) and, subsequently, 
inhibits the translation or targets the degradation of the bound mRNAs 
(Mirra et al. 2018).  
 
 
 
Figure 2.1 Biogenesis of miRNA (Devaux et al. 2015). 
 
 
The nascent transcript, referred to as the pri-miRNA, is usually several 
hundred nucleotides in length and contains one or more hairpin structures. 
The miRNA-specific processing begins in the nucleus with the cleavage at 
the stem-loop formations by an RNase III-like enzyme, known as Drosha, 
which acts in concert with co-factors, including DiGeorge syndrome critical 
region 8 (also known as Pasha in flies and nematodes), at the level of the 
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microprocessor complex. The result is a 70-nucleotide long stem loop 
precursor, known as the pre-miRNA, which is then exported to the cytosol 
by exportin 5 and Ran-GTP through nuclear pores. Once in the cytoplasm, 
Dicer, another RNase III-like endonuclease, recognizes the hairpin-shaped 
pre-miRNA hairpin and cuts the terminal-loop to generate a RNA duplex, 
20–22 nucleotides in length. To stabilize the interaction of Dicer with the 
pre-miRNA, the Dicer cleavage takes place in a large complex, which 
includes TRBP or TARBP2 (the human immunodeficiency virus 
transactivating response RNA-binding protein). The resulting miRNA 
duplex is composed of the mature miRNA and the base-paired passenger 
strand, sometimes indicated as the miRNA* strand. The final step consists 
in the incorporation of the miRNA duplex into the final effector complex, 
namely the RNA-induced silencing complex (RISC), where it is loaded onto 
an Argonaute (Ago) protein. At this point, the strand that exhibits less stable 
base pairing at the 5′ end remains associated with the Ago protein (mature 
miRNA), while the other is unwound from the duplex and typically 
degraded by the RISC (miRNA* strand), although some miRNAs* are 
thought to regulate gene expression like mature miRNAs (Fig.2.1). 
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2.4 Influence of miRNAs in insulin signalling pathway and insulin 
resistance 
 
Recent studies have highlighted the role of miRNAs in the regulating the 
expression of endothelial genes involved in angiogenesis, EC proliferation 
and function. In increasing number of studies on miRNAs related to human 
diseases has pointed out that these molecules play a significant role in 
controlling insulin pathway beside other cellular pathways. The 
involvement of miRNAs in T2DM was first confirmed by Poy et al. (2007), 
who have demonstrated the role of miR-375 in the control of insulin 
secretion. Up to date, a large number of miRNAs is known to be connected 
with the cascade of pathways related to T2DM. Among these miR-33a and 
miR-33b have a role in the insulin signalling by controlling AKT 
phosphorylation and they also target the IRS-2 and insulin signalling 
pathways in the liver (Dávalos et al. 2011). There are other evidence 
demonstrating that miR-144 directly inhibits IRS1 (a key molecule in insulin 
signalling), Moreover, the miR-322 regulates insulin signalling pathway and 
protects against metabolic syndrome-induced cardiac dysfunction in mice 
(Marchand et al. 2016), while miR-320 favors insulin sensitivity in insulin 
resistant conditions by regulating the insulin-IGF-1 signalling pathways. 
Different are the miRNAs expressed in the ECs. miR-126 is involved in the 
inflammatory response, and it has an essential role in the maintaining 
vascular integrity and homeostasis after tissue damage, by enhancing 
endothelial repair capacity. The endothelium-specific miRNA, miR-92a, 
negatively regulates EC-derived production of NO and its upregulation has 
been associated with atherosclerosis and myocardial injury. On the contrary, 
miR-92a inhibition may play an important role in preventing neointimal 
hyperplasia since NO production by ECs inhibits VSMCs proliferation 
(Pujol-López et al. 2017). Hence, normalizing the expression of the 
dysregulated miRNAs may serve as a therapeutic approach in controlling 
the development and/or progression of insulin resistance and endothelial 
dysfunction thus preventing cardiovascular disease (Fig. 2.2) 
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Figure 2.2 MicroRNAs (miRNAs) targeting insulin signalling mediators. Following the 
binding to insulin receptor (IR), insulin induces the activation of phosphatidylinositol 3-
kinase (PI3K)/AKT pathway responsible for the metabolic effect of insulin through the 
increase of glucose uptake, the increase of glycogen synthesis and the reduction of 
gluconeogenesis. On the other hand, insulin activates the mitogen-activated protein kinase 
(MAPK) pathway increasing cellular proliferation. miRNAs directly targeting critical 
nodes of insulin signalling are reported in the red boxes in figure. Thin green arrows 
indicate activation, while red T arrows indicate direct inhibition. Thick green arrows 
indicate inhibitory phosphorylation. (p) Indicates a phosphate group. Abbreviations: 
IRS1/2, insulin receptor substrate 1/2; PIP3, phosphatidylinositol 3,4,5-triphoshate; PIP2, 
phosphatidylinositol 4,5-bisphoshate; PDK1, phosphoinositide-dependent kinase 1; 
mTORC2, mammalian target of rapamycin complex 2; FOXO1, forkhead box protein O1; 
GSK3, glycogen synthase kinase 3; GS, glycogen synthase; AS160, AKT substrate of 
160 kDa; GLUT4, glucose transporter 4; Grb2, growth factor receptor-bound protein 2; 
SOS, son of seven less; KRAS, Kirsten rat sarcoma viral oncogene homolog (proto-
oncogene); RAF, RAF proto-oncogene serine/threonine-protein kinase; MEK, mitogen-
activated protein kinase kinase; ERK, extracellular signal-regulated kinase (Mirra et 
al.2017). 
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2.5 Aim  
 
The increased formation of MGO is one of the mechanisms proposed as the 
cause of insulin resistance and an important contributor to the development 
of vascular complications in chronic hyperglycemia. An interesting new 
concept concerns the possibility that MGO may also affect gene expression 
through mediating epigenetic changes including miRNAs modulation. We 
and others have demonstrated that MGO leads to endothelial insulin 
resistance. In light of these recent findings, we have examined here the 
involvement of miRNAs as potential culprits behind the action of MGO on 
the endothelium, in order to explain the molecular mechanisms responsible 
for the MGO-dependent impairment of the endothelial insulin sensitivity 
previously demonstrated (Nigro et al. 2014). 
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2.6 Results 
 
2.6.1 Effect of MGO accumulation on miRNAs expression in endothelial 
cells. 
 
Insulin resistance is a major risk factor for type 2 diabetes (Zang et al. 2017), 
which promotes endothelial dysfunction, in the long term. It is known that 
increased MGO levels impair the endothelial function in various ways and 
in different body districts, (Nigro et al. 2017), leading to the development of 
endothelial dysfunction, principal cause of the cardiovascular diseases 
(Stehouwer et al. 1997, De Caterina 2000, Schalkwijk et al. 2005). 
Nevertheless, the underlying molecular mechanisms are not fully 
understood yet. In order to evaluate the MGO effect on miRNAs and their 
impact on pathophysiological pathways of insulin action, we have analyzed 
the expression profile of 84 miRNAs experimentally identified and/or 
bioinformatically predicted to be involved in diabetes-related biological 
processes, by the use of a miRNA PCR Array.  Mouse aortic endothelial 
cells (MAECs) have been treated with MGO 500 μmol/l for 16 hours and 
12 of 84 tested miRNAs resulted to be over or under the arbitrary chosen 
cut-off (± log 0.5-fold changes vs untreated cells). Among these, 5 miRNAs 
are up-regulated and 7 are down-regulated in MGO treated MAECs 
compared to control untreated cells. To validate these data, the expression 
of these 12 miRNAs was then tested by Real Time-PCR and the differential 
expression of miR-126, miR-190a, miR-214 and miR-450a was confirmed 
(figure 2.3). It is following described the study we have performed on the 
role of these differently expressed miRNAs on insulin signal transduction in 
endothelial cells. 
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Figure 2.3 MGO effect on miRNAs expression. The expression of miRNAs resulted to be 
differentially expressed in the PCR array was tested by Real Time-PCR in MAECs treated 
with 500 μmol/lMGO. The bars in the graph represent the mean ± SD of the expression 
units relative to U6 snRNA levels, used as housekeeping gene. Control levels of miRNAs in 
not treated MAECs are referred as 1 (dotted line). Statistical significance was evaluated 
using the Student's t-test; ⁎p≤0.05, ⁎⁎⁎p≤0.001. 
 
 
2.6.2 The role of miR-190a on MGO-mediated insulin-resistance in 
endothelial cells. 
 
To demonstrate the role of miR-190a in endothelial insulin signalling, its 
expression was antagonized by transfecting the miR-190a inhibitor in 
MAECs cells stimulated or not with insulin. Interestingly, similarly to 
MGO-treated cells, the inhibition of miR-190a significantly decreases the 
insulin-induced tyrosine phosphorylation of IRS1 (Fig. 2.4 a) and Akt 
phosphorylation, both on ser473 and thr308 (Fig. 2.4 b), compared to control 
MAECs transfected with a scramble miRNA, without affecting the insulin-
receptor (IR) phosphorylation (Fig. 2.4 a). In addition, as shown in figure 
2c, insulin-dependent eNOS activation is impaired by the inhibition of miR-
190a. Indeed, we have seen a reduction of phosphorylation on ser1177 and 
a loss of de-phosphorylation in thr497 in MAEC cells treated with insulin, 
compared to scramble treated cells. Consistent with eNOS activation, 
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insulin stimulation induces a ~1.4- fold increase of NO release in scramble-
treated cells, as expected, while no increase of NO levels is revealed in the 
culture medium from MAECs transfected with miR-190a inhibitor (Fig.1d). 
Furthermore, as in MGO-treated cells, the inhibition of miR-190a increases 
basal ERK 1/2 phosphorylation (Fig. 2.4 e). Thus, these data demonstrate 
that, independently from MGO exposure, the reduction of miR-190a levels 
is sufficient to affect ERK 1/2 activation and insulin-dependent 
IRS1/Akt/eNOS pathway in MAECs. 
 
 
 
 
 
 
 
 
 
 
 
MGO and miRNAs 
83 
 
 
  
Figure 2.4 Effect of miR-190a inhibitor on insulin sensitivity in MAECs. MAECs were 
transfected with a negative control (scramble; white and black bars) or with the inhibitor 
of miR-190a (gray bars) and incubated with 500 μmol/l MGO (black bars) where indicated. 
They were then stimulated or not with 100 nmol/l insulin (Ins) for 10 min. Protein lysates 
obtained from these cells were analyzed by Western Blot with anti-p-tyr-IR, anti-p-tyr-IRS1, 
anti 14-3-3 (a), anti-p-ser473-Akt, anti-p-thr308-Akt, anti-Akt (b), anti-p-ser1177-eNOS, 
anti-p-thr497-eNOS, anti-eNOS (c), anti-p-ERK1/2 and anti-ERK1/2 antibodies (e). 
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Protein levels were quantified by the densitometric analysis of at least 3 independent 
experiments. The bars in the graph represent the means ± SEM of the percent (%) over 
control. (d) The culture medium was collected and tested for NO concentration by a 
colorimetric kit assay. The bars in the graph represent the increase of NO medium content 
after insulin stimulation over the control. The basal NO medium concentration is referred 
as 1.0 (dotted line). Values are expressed as means ± SD of triplicate determinations. 
Statistical analysis was evaluated using the Student's t-test; ⁎⁎p ≤0.01 ,⁎⁎⁎p≤0.001 (+insulin 
vs − insulin); ##p≤0.01(MGO scramble +insulin and miR-190a inhibitor +insulin vs 
scramble untreated +insulin);$$$p≤0.001 (MGO scramble − insulin and miR-190a inhibitor 
− insulin vs scramble untreated − insulin). 
 
Next, wondering how the reduced expression of miR-190a may be crucial 
in mediating the MGO effect on endothelial insulin-sensitivity, miR-190a 
levels were increased by transfecting cells with a miR-190a mimic. As 
previously demonstrated by our group (Nigro et al. 2014), insulin-induced 
IRS1, but not IR, phosphorylation (Fig. 2.5a), ser473 and thr308-Akt 
phosphorylation (Fig. 2.5b) and the downstream ser1177-eNOS 
phosphorylation (Fig. 2.5c) are impaired in MAECs treated with MGO. 
Interesting, the overexpression of miR-190a in MGO-treated cells, at least 
partly, prevents the MGO deleterious effects on  
the insulin-stimulated activation of IRS1/Akt/eNOS (Fig. 2.5a–c). 
Interestingly, the overexpression of miR-190a also rescues the insulin-
induced NO release in MGO-treated MAECs. Moreover, the MGO-induced 
ERK 1/2 hyperactivation is prevented by the transfection of the miR-190a 
mimic (Fig. 2.5e). 
The data described so far show that miR-190a is a key player in the MGO-
dependent impairment of insulin sensitivity in MAECs. 
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Fig. 2.5. Effect of miR-190a mimic on insulin sensitivity in MAECs. MAECs were 
transfected with a negative control (scramble; white and black bars) or with the mimic of 
miR-190a (gray bars), and incubated with 500 μmol/l MGO, where indicated. They were 
then stimulated or not with 100 nmol/l insulin for 10 min. (a, b, c and e) Protein lysates 
obtained from these cells were analyzed by Western Blot as described in figure legend 2. 
The bars in the graph represent the means ± SEM of the percent (%) over control. (d) NO 
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production was evaluated as reported in figure legend 2. The bars in the graph represent 
the increase of NO medium content after insulin stimulation over the control. The basal NO 
medium concentration is referred as 1.0 (dotted line). Values are expressed as means ± SD 
of triplicate determinations. Statistical analysis was evaluated using the Student's t-test;⁎⁎p 
≤0.01,⁎⁎⁎p≤0.001 (+insulin vs − insulin);#p≤0.05,##p≤0.01,###p≤0.001 (MGO scramble 
+insulin vs scramble untreated +insulin);†p≤0.05,††p≤0.01 (miR-190a mimic +insulin vs 
MGO scramble +insulin);$$$p≤0.001 (MGO scramble − insulin vs scramble untreated − 
insulin). 
 
 
2.6.3 miR-190a down-regulation plays a role in MGO-induced endothelial 
insulin resistance by increasing KRAS protein levels. 
 
We have previously published that MGO exposure affects insulin sensitivity 
in MAECs through the hyperactivation of ERK1/2 (Nigro 2014). Thus, in 
order to establish whether ERK 1/2 activation could be up- or down-stream 
the MGO-induced miR-190a down-regulation, ERK 1/2 phosphorylation 
was prevented by the chemical inhibitor UO126.  
Pre-treatment with the MAPK ERK Kinase (MEK) inhibitor U0126 does 
not affect the MGO-induced miR-190a reduced expression (Fig. 2.6a).  
Interestingly, the protein protein levels of GTPase Kirsten Rat Sarcoma 
Viral Oncogene Homolog (KRAS), which is one of the validated targets of 
miR-190a are increased by both MGO exposure and miR-190a inhibitor 
transfection (Fig. 2.6 b). Conversely, reduced levels of KRAS are shown, 
when miR-190a expression is increased by miR-190a mimic transfection, 
even in presence of MGO (Fig. 2.6 c). Furthermore, the role of KRAS in the 
MGO effect on insulin signalling was evaluated by transfecting MAECs 
with a specific siRNA for KRAS. KRAS protein levels are reduced by 
siKRAS compared to MGO-treated cells transfected with a scramble 
siRNA, used as negative control (Fig. 2.6d). Silencing of KRAS prevents 
ERK 1/2 basal activation as well as IRS1 phosphorylation on ser616 (Fig. 
2.6 d), also rescuing the insulin-dependent Akt and eNOS activation (Fig. 
2.6e). Together, these results indicate that miR-190a down-regulation 
mediates the MGO effect on endothelial insulin sensitivity, at least in part, 
by increasing the levels of its target KRAS. 
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Fig. 2.6. The role of KRAS in MGO-mediated effect. (a) MAECs were pre-treated with 
the MEK inhibitor U0126 15 μmol/l and then treated with MGO 500 μmol/l. Total RNA was 
extracted from these cells and analyzed by Real Time-PCR. The bars in panel a represent 
the means ± SD of miR-190a expression units relative to U6 snRNA levels. (b, c) MAECs 
were transfected with a negative control (scramble inhibitor or scramble mimic; white 
bars) or treated with 500 μmol/l MGO (black bars) and transfected with the inhibitor (b) 
and the mimic (c) of miR-190a (gray bars), were indicated. Protein lysates obtained from 
these cells were analyzed by Western Blot with anti-KRAS and anti-α-tubulin antibodies. 
Protein levels were quantified by the densitometric analysis of at least 3 independent 
experiments. The bars in the graph represent the means ± SEM of the percent (%) over 
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control. (d, e) MAECs were transfected with a negative control, treated or not with MGO 
500 μmol/l, or transfected with an interfering RNA specific for KRAS, as indicated. Protein 
lysates obtained from these cells were analyzed by Western Blot with anti-p-ser616-IRS1, 
anti-p-ERK1/2, anti-KRAS (d), anti-p-ser473-Akt, anti-p-thr497-eNOS antibodies (e). Anti-
α-tubulin antibody was used as loading control. Statistical analysis was evaluated using 
the Student's t-test; ⁎⁎⁎p≤0.001 (MGO vs control untreated or scramble); ##p≤0.01 (miR-
190a inhibitor and mimic vs scramble); †p≤0.05(MGO + miR190a mimic vs MGO). 
 
2.6.4 Effect of MGO on insulin pathway phosphatases, targets of 
miRNAs down-regulated by MGO. 
 
Besides miR-190a, we evaluated the possible contribution of other 
differently expressed miRNAs in the insulin signalling alteration in MAECs 
exposed to MGO. To this aim, the putative targets have been checked by the 
use of mirWalk database (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk/). Among these, the phosphatase and 
tensin homolog (PTEN), protein tyrosine phosphatase 1B (PTP1B), PH 
domain leucine-rich repeat protein phosphatase 1 and 2 (PHLPP1 and 
PHLPP2) play an important role in the regulation of insulin signalling. As 
shown in Figure 2.7, treatment of MAECs with MGO has no effect on the 
protein levels of PTEN (Fig. 2.7a), PTP1B (Fig. 2.7 b) and PHLPP1 (Fig. 
2.7c). By contrast, protein levels of PHLPP2 are 4-fold increase in MGO-
treated MAECs compared to the untreated control cells (Fig. 2. 7d). 
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Figure 2.7 Effect of methylglyoxal (MGO) on miR-214 and miR-126 target phosphatases 
of insulin signalling mediators. Mouse aortic endothelial cells (MAECs) were treated with 
500 μmol/L MGO for 16 h. Protein lysates obtained from these cells were analyzed by 
Western blot with anti-PTEN (a) anti-PTP1B (b) anti-PHLPP1 (c) and anti-PHLPP2 
antibodies (d). Protein normalization was performed using α-tubulin antibody. Exposure 
timing was of 1 min for blots in panels (a, c, d), and 2 min for blots in panel (b). Protein 
levels were quantified by the densitometric analysis of at least three independent 
experiments. Bars in the graphs represent the mean ± SD of the percent (%) over control 
(−MGO). Statistical analysis was evaluated using the Student’s t-test; *** p ≤ 0.001. 
 
 
2.6.5 Effect of the modulation of the miR-214 and miR-126 on PHLPP2 
protein levels in MAECs. 
 
The preliminary bioinformatic analysis indicated PHLPP2 as a potential 
target of both miR-214 AND Mir-126. In the light of these informations, we 
have modulated the expression of both miR-214 and miR-126 in MAECs. 
We have first transfected MAECs with a specific antisense inhibitor for 
miR-214 (miR-214 inhibitor) and surprisingly, as shown in figure 8a, the 
reduction of miR-214 induces a dose-dependent increase of PHLPP2 protein 
levels. Differently, we have not observed any significant difference between 
MAECs transfected with a specific antisense inhibitor for miR-126 (miR-
126 inhibitor) and MAECs transfected with a non-targeting antisense 
inhibitor (control inhibitor) (Figure 8b). In accordance with the previous 
results, a significant reduction in PHLPP2 levels is observed in MAECs 
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overexpressing miR-214, when transfected with 50 nmol/L of a RNA 
oligonucleotide which specifically mimics miR-214 (miR-214 mimic) 
(figure 8c). Conversely, the MAEC cells transfected with a RNA 
oligonucleotide mimicking miR-126 (miR-126 mimic) did not show any 
difference in levels PHLPP2 compared with cells transfected with a non-
targeting control oligonucleotide (control mimic). Taken together, these 
results show that miR-214, but not miR-126, is able to modulate the protein 
levels of PHLPP2 in MAECs. 
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FIGURE 2.8 Effect of miR-214 and miR-126 modulation on PHLPP2 protein levels in 
MAECs. MAECs were transfected with different concentrations (0.5, 5, and 50 nmol/L) of 
miR-214 (a) and miR-126 (b) inhibitor (miR-214 In and miR-126 In), or miR-214 and miR-
126 mimic (miR-214 M and miR-126 M) (c). Transfection with a non-targeting antisense 
inhibitor (Ctr In; (a, b)), and a non-targeting control oligonucleotide (Ctr M; (c)) were 
used as negative controls. Forty-eight hours after transfection, cells were collected, and 
protein lysates were analyzed by Western blot with anti-PHLPP2 and anti-α-tubulin 
antibodies. Exposure timing was 4 min for blots in panels (a), 2 min for blots in panels (b) 
and 20 min for blots in panel (c). Protein levels were quantified by the densitometric 
analysis of at least three independent experiments. Bars in the graphs represent the mean 
± SD of the percent (%) over control (Ctr In or Ctr M) 0.5 nmol/L. Statistical analysis was 
evaluated using Student’s t-test; ** p ≤ 0.01; *** p ≤ 0.001. 
  
2.6.6 Effect of the modulation of miR-214 on PHLPP2 levels in MAECs. 
 
As shown in the figure 9, MAECs transfected with the miR-214 inhibitor 
show an increase of PHLPP2 levels by about 4-fold, similarly to that 
observed in both MGO-treated control cells and miR-214 inhibitor plus 
MGO co-treated cells. In addition, in the presence of MGO, the transfection 
of MAECs with the miR-214 mimic reverses the effect due to MGO, leading 
to a 2.5-fold reduction of PHLPP2 levels. Therefore, these data demonstrate 
that miR-214 mediates the effect of MGO on the PHLPP2 expression.  
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Figure 2.9. Effect of miR-214 mimic and miR-214 inhibitor on PHLPP2 levels in MAECs 
with or without MGO. MAECs were transfected with a non-targeting antisense inhibitor 
(Ctr In 0.5 nmol/L; (a)) and a non-targeting control oligonucleotide (Ctr M 50 nmol/L; (b)) 
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(white and black bars), with miR-214inhibitor (miR-214 In 0.5 nmol/L; (a)) or miR-214 
mimic (miR-214 M 50 nmol/L; (b)) (gray bars). Where indicated, MAECs were treated with 
MGO for 16 h. Protein lysates obtained from these cells 48 h after transfection were 
analyzed by Western blot with anti-PHLPP2 and anti- 
-tubulin antibodies. Exposure timing was of 2 min for PHLPP2 blots and 10 min for  
-tubulin blots. Protein levels were quantified by the densitometric analysis of at least three 
independent experiments. Bars in the graphs represent the mean ± SD of the percent (%) 
over control (Ctr M and Ctr In). Statistical analysis was evaluated using the Student’s t-
test; ** p ≤ 0.01; *** p ≤0.001. 
 
 
In order to prove a direct regulation of PHLPP2 expression by miR-214, a 
mi Script Target Protector (TP) specific for the binding site of miR-214 on 
the 3′ untranslated region (UTR) of the mouse PHLPP2 has been used to 
treat MAECs. The data obtained demonstrate that the decrease of PHLPP2 
protein levels in MAECs transfected with miR-214 mimic, is no longer 
observed in MAECs transfected with both the mi Script Target Protector 
(TP) and miR-214 mimic (Figure 10a). In line with this, the luciferase 
reporter assay performed in MAECs using a construct in which the PHLPP2-
3’UTR is cloned immediately downstream of the Firefly luciferase confirms 
a miR-214-dependent regulation of PHLPP2. Indeed, the transfection of 
miR-214 mimic induces a 25% reduction of luciferase activity driven by the 
PHLPP2-3’UTR, while no effect on luciferase activity is induced by miR-
214 mimic in the empty control vector-transfected cells (figure 10b). 
Together this data, demonstrate that miR-214 binds the PHLPP2-3’UTR 
region and, therefore, regulates its expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MGO and miRNAs 
 
 94 
 
 
 
 
 
Figure 2.10. Effect of miR-214 on PHLPP2 regulation. (a) MAECs were transfected with 
a non-targeting control oligonucleotide (Ctr M; white bars) or miR-214 mimic (miR-214 
M 50 nmol/L; black bars). Where indicated, MAECs were co-transfected with mi Script 
miR-214 Target Protector (miR-214 TP 0.1 nmol/L). Protein lysates obtained from 48 h 
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transfected MAECs were analyzed by Western blot with anti-PHLPP2 and anti-α-tubulin 
antibodies. Exposure timing of blots was of 2 min. Protein levels were quantified by the 
densitometric analysis of at least three independent experiments. Bars in the graphs 
represent the mean ± SD of the percent (%) over control (Ctr M). (b) MAECs were 
transfected for 24 h with non-targeting control oligonucleotide (Ctr M 50 nmol/L; white 
bars) or miR-214 mimic (miR-214 M 50 nmol/L; black bars) in the presence of the pEZX-
MT06 control reporter vector or the pEZX-MT06/PHLPP2-30UTR reporter vector. Firefly 
and Renilla luciferase activities were determined in cell lysates under each experimental 
condition. Results are normalized to Renilla activity. Bars in the graphs represent the mean 
± SD of the fold over control (Ctr M). Statistical analysis was evaluated using Student’s t-
test; *** p ≤ 0.001. 
 
 
2.6.7 Role of miR-214 on MGO-mediated endothelial insulin-resistance. 
 
Once demonstrated the regulation of PHLPP2 by miR-214, to prove a role 
of miR-214 on MGO-mediated endothelial insulin-resistance, we analyzed 
the effect of miR-214 inhibitor and miR-214 mimic on insulin-dependent 
phosphorylation of Akt. As shown figure 11, MGO induces a reduction of 
insulin-induced Akt phosphorylation, in MAECs transfected with the 
control inhibitor, compared to the control cells not exposed to MGO. 
Similarly, the transfection of MAECs with miR-214 inhibitor significantly 
decreases the insulin-stimulated Akt phosphorylation compared to control 
cells. Differently, the transfection the MAEC with a miR-214 mimic 
prevents the MGO deleterious effect on the insulin-dependent Akt 
phosphorylation (figure 11 b). 
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Figure 2.11. Effect of miR-214 modulation on insulin-dependent Akt activation in 
MAECs. MAECs were transfected with a non-targeting antisense inhibitor (Ctr In 0.5 
nmol/L; (a)) or a non-targeting control oligonucleotide (Ctr M 50 nmol/L; (b)) (white and 
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black bars), with miR-214 inhibitor (a) or miR-214 mimic (b) (miR-214 In 0.5 nmol/L or 
miR-214 M 50 nmol/L; gray bars). Where indicated, MAECs were treated with 500 _mol/L 
MGO (black bars) for 16 h before harvesting. After 48 h of transfection, cells were 
stimulated or not with 100 nmol/L insulin for 10 min. Protein lysates were analyzed by 
Western blot with p-ser473-Akt and Akt antibodies. Exposure timing was of 30 seconds. 
Protein levels were quantified by the densitometric analysis of at least three independent 
experiments. p-ser473-Akt levels were normalized to Akt total levels. Bars in the graphs 
represent the mean _ SD of the percent (%) over control (Ctr In and Ctr M). Statistical 
analysis was evaluated using the Student’s t-test; * p ≤ 0.05; ** p≤ 0.01; *** p≤ 0.001 
 
 
Finally, in addition to the above reported experiments carried out in vitro in 
MAECs, we have also validated the effect of MGO on miR-190a and miR-
214 in vivo. To this aim, aortae were isolated from non-diabetic Glo1-KD 
mice, described to have high levels of MGO-modified proteins (Queisser et 
al. 2010, Giacco et al. 2014), and miR-190a and miR-214 levels were 
analyzed by Real Time-PCR. As shown in figure 2.12, the vascular 
expression of the both miR-190a and miR-214 are reduced by 60% and 45% 
respectively in Glo1-KD mice compared to their WT littermates. Moreover, 
we performed Western Blot analysis with the proteins isolated from both 
WT and Glo1-KD mice, stimulated or not with insulin. The data obtained 
show that insulin stimulation induces an 8- and 3-fold increase of ser473-
Akt and ser1177-eNOS phosphorylation, respectively, in the aortae from 
WT mice. Conversely, the aortae from Glo1-KD mice show a 60% decrease 
of insulin-dependent Akt activation and a 50% decrease of eNOS activation, 
compared to WT mice (Fig. 5b).  
This is an interesting result, showing that a mouse model, which is prone to 
accumulate MGO-modified proteins (Queisser et al. 2010), also shows 
reduced levels of miR-190a, miR-214 and vascular insulin sensitivity. 
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Fig. 2.12 Effect of MGO and vascular insulin sensitivity in vivo. (a) miR-190a expression 
and miR-214 (b) were measured by Real Time-PCR in aortae from Glo1-KD and WT mice. 
The bars in the graphs represent the mean ± SD of the expression units relative to U6 
snRNA levels, used as housekeeping gene. Statistical significance was evaluated using the 
Student's t-test; ⁎⁎⁎p≤0.001. (c) Proteins were isolated from aortae of Glo1-KD and WT 
mice, receiving or not an i.p. bolus of insulin, and then analyzed by Western Blot with anti- 
p-ser473-Akt, anti-p-ser1177-eNOS and anti-α-tubulin. Blots are representative of at least 
four mice. 
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2.7 Discussion 
 
MGO is a highly reactive dicarbonyl compound which is formed as a by-
product of glycolysis (Rabbani et al 2014). It is a major precursor of AGEs, 
reacting non-enzymatically with amino acid residues (e.g., Lys and Arg) 
located in the active sites of proteins and thereby causing their loss of 
function. (Ahmed and Thornalley 2006, Mirra et al. 2017) MGO levels 
increase in condition of hyperglycemia and reduced activity of the 
glyoxalase system. Plasma levels of MGO are increased in patients with DM 
(Beisswenger et al. 2001) and its abnormal accumulation contributes to the 
damage of various tissues. (Mirra et al 2017, Beisswenger 2014), also 
disturbing the insulin signalling pathway (Fiory et al 2011, Guo et al.2009 
Riboulet-Chavey et al.2006). Emerging evidence have highlighted the 
harmful effect of MGO on the pathogenesis of insulin resistance by means 
of direct functional modifications in the molecular components of the insulin 
signalling pathway. For instance, an impairment in the insulin-stimulated 
activation of IRS-1 has been observed in the adipose tissue of fructose fed 
rats and in 3T3-L1 adipocytes (Jia and Wu 2007), in L6 muscle cells 
(Riboulet-Chavey) and in INS-1E β-cells treated with MGO (Fiory et al. 
2011). Moreover, we have previously demonstrated that the exposure of 
both endothelial cells in vitro and mice to MGO impairs the insulin-
dependent IRS-1/Akt/eNOS pathway and the consequent release of NO. In 
addition, we demonstrated that the MGO-dependent ERK 1/2 hyper-
activation is responsible, at least in part, for the negative effect of MGO on 
the IRS-1/Akt/eNOS signalling pathway (Nigro et al. 2014). More recently, 
several studies, demonstrated that MGO alters gene expression by 
modifying transcription factors (Yao et al. 2007, Thangarajah et al 2009, 
Laga et al. 2007). An interesting new concept concerns the possibility that 
MGO may also affect gene expression through changes in DNA methylation 
(Palsamy et al. 2014), histone modifications (El-Osta et al. 2008) and 
miRNA expression (Liu H et al 2014, Shan-Shan et al. 2015). In particular, 
we have focused our attention on miRNAs as potential culprits behind the 
action of MGO on the endothelium in order to identify the molecular 
mechanisms responsible for the MGO-dependent impairment of the 
endothelial insulin sensitivity previously demonstrated (Nigro et al. 2014). 
To this aim, the expression profile of 84 diabetes-associated miRNAs were 
evaluated through a diabetic-specific array platform. Among these, we 
validated the reduced expression of 4 miRNAs in MGO-treated MAECs: 
miR-126, miR-190a, miR-214 and miR450a. We have provided the first 
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evidence that MGO down-regulates the expression of miR-190a and miR-
214 both in MAECs, and in the vascular tissue of mouse model of MGO 
accumulation. Glo1-KD mice, represent a suitable animal model to study 
the effects of MGO accumulation. They develop signs of diabetic 
complications and, besides the impaired endothelium-dependent 
vasodilation described in the chapter 1 of this thesis, we have found an 
impaired insulin sensitivity in the aortae tissue of Glo 1 KD mice compared 
to WT mice. Therefore, a vascular insulin-resistance associates with reduced 
levels of miR-190a and miR-214 in vivo, as well. We proved the identified 
miRNAs in the impaired endothelial insulin-sensitivity by gain and loss of 
function experiments. Interestingly, the inhibition of miR-190a, mimicks the 
MGO-dependent effect on the insulin sensitivity in the endothelial cells, as 
it is sufficient to cause insulin resistance and impair the insulin-induced NO 
secretion. In a previous study, we have demonstrated that the MGO-
dependent ERK 1/2 hyperactivation is responsible, at least partly, for the 
negative effect of MGO on the IRS1/Akt/eNOS transduction. Therefore, to  
the aim of establishing how MGO mediates the miR-190a down-regulation 
in MAECs, we have investigated the ERK 1/2 pathway. Moreover, a 
decreased transcription of miR-190a has recently been described to be 
dependent on ERK 1/2 nuclear activity in rat primary hippocampal neuron 
cultures and in mouse hippocampi (Zheng et al 2010, Zheng, Chu  et al. 
2010) However, in MAECs cells treated with UO126, a highly selective 
inhibitor of MEK Kinase, MGO still affected the miR-190a expression in 
MAECs, thus indicating that MGO modulates the miR-190a expression 
independently of ERK 1/2 in the endothelial cells. By contrast, when we 
induced alterations in the miR-190a levels, an inverse correlation between 
the miR-190a and ERK 1/2 phosphorylation levels was observed. This result 
suggests that the MGO-dependent hyper-activation of ERK 1/2 might be 
mediated by miR-190a. In order to clarify how miR-190a mediates the 
hyper-activation of ERK 1/2 we first tested whether alterations in the miR-
190a levels were able to modulate the expression of miR-190a. However, 
we did not observe any difference in the protein levels of ERK 1/2 in 
MAECs when alterations in the miR-190a levels were induced. Afterwards, 
we identified the MAPK signalling pathway as one of the most enriched 
molecular pathways in the miR-190a target set, achieved through the 
combined results of 4 well-known tools for miRNA target prediction 
(miRanda (Enright et al. 2003), Target scan (Lewis et al. 2003), RNA22 
(Miranda et al 2006) and miRWalk (Dweep et al. 2011)). Among the 42 
potential targets of miR-190a related to the MAPK signalling pathway, 
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KRAS has an intrinsic GTPase activity which act upstream ERK ½ (Cox 
and Der 2010). For this reason, we have evaluated the protein levels of 
KRAS, and the data obtained show that alterations in the miR-190a levels 
were able to modulate this target in MAECs. This result is supported by the 
study carried out by Hao et al. demonstrating, that KRAS is directly 
regulated by miR-190a in HCT166 cells via a highly conserved binding site 
(Yang et al 2014). We further prove here the role of KRAS in the MGO-
induced endothelial insulin-resistance by showing that its silencing in 
MAECs prevents the MGO effect on both the basal ERK 1/2 hyper-
phosphorylation and the reduced insulin-stimulated IRS-1/Akt/eNOS 
signalling pathway. Besides miR-190a, we have also evaluated a possible 
role on the insulin-signalling of the other miRNAs found to be down-
regulated by MGO. While very little is known about miR-450a to support 
its selection as a candidate for further investigation on its potential role in 
MGO-treated MAECs, previous studies highlight miR-214 and miR-126 
attractive candidates, since they have a role in the control of endothelial cell 
function. Indeed, it has been demonstrated that miR-125 downregulates 
IRS1, suppressing AKT activation (Duan et al 2015, Ryu. While, miR-214 
has been reported to activate the PI3K/Akt signalling by targeting PTEN 
expression in several cell types, (besides targeting IRS and Akt in C2C12 
myoblasts Wang et al. 2016, Yang et al. 2008, Zhang and Zhang 2017, Liu 
et al. 2017, Yang et al. 2013, Xin et al. 2016). As we have found no 
difference in the levels of the key components of the IRS1/Akt/eNOS 
signalling in MAECs exposed to MGO, we have shifted our focus towards 
negative regulators of the insulin signalling. Indeed, their upregulation as a 
consequence of the reduced levels of miRNAs induced by MGO, would 
provide a reasonable explanation for the decrease of insulin responsiveness 
observed in MGO-treated MAECs. Through several bioinformatics tools, 
we have identified different phosphatases as a potential target of both miR-
214 and miR-126. We have evaluated the effect of MGO on the levels of the 
following proteins: PTP1B, which binds and subsequently dephosphorylates 
the insulin receptor (Wang et al. 2001); the lipid phosphatase PTEN, which 
dephosphorylates PIP3 and antagonizes the PI3K signalling (Conche and 
Sauer  2014); and the serine phosphatases PHLPP1 and PHLPP2, which 
specifically dephosphorylates Akt at the serine 473 residue and inactivates 
it.  We have not observed any alterations in the protein levels of PTP1B and 
PHLPP1 in MAECs treated with MGO. Surprisingly, despite PTEN is a 
widely validated target of miR-214, in our experimental model, its protein 
levels are not modified by MGO. One possible explanation for the lack of 
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PTEN regulation by miR-214 in our cellular model is that the binding site 
for miR-214 in the 3’UTR of mouse PTEN overlaps with the binding site 
for several other miRNAs in accordance with the microRNA.org prediction. 
This suggests that other miRNAs highly expressed in MAECs may regulate 
PTEN in a mutually exclusive fashion and independently from any changes 
in miR-214 levels upon MGO treatment. Based on our search on 10 different 
miRNA target prediction programs to retrieve information on any 
interaction between PHLPP2 and specific miRNAs, PHLPP2 results to be a 
predicted target of both miR-214 and miR-126. Interestingly, the inhibition 
of the endogenous miR-214 in MAECs is sufficient to cause a significant 
increase in PHLPP2 protein levels. This increase is comparable to that 
induced by MGO, while miR-214 overexpression results in decrease of 
PHLPP2 levels in MAECs the phosphatase levels are significantly 
decreased. Differently, we have not observed alterations in PHLPP2 protein 
levels, after modulation   miR-126 in MAECs. Taken together, these results 
suggest an inverse correlation between PHLPP2 and miR-214, but not with 
miR-126, supporting the bioinformatic target prediction only for miR-214. 
Moreover, for the first time, we prove a direct regulation of miR-214, as 
demonstrated by the experiments performed with both PHLPP2 by a target 
site protector specific for the binding site of miR-214 in the 3’UTR of mouse 
PHLPP2 and a reporter gene assay with the 3’UTR of mouse PHLPP2 
cloned downstream of the Firefly luciferase gene. In order to test the role of 
miR-214 in the MGO effect on PHLPP2 levels in MAECs, miR-214 was 
inhibited or overexpressed in presence of MGO. No further increase is 
observed in the former case, thus excluding that two different mechanisms 
are due to miR-214 and MGO. Differently, a reversion in the PHLPP2 
expression is obtained when the MGO-dependent downregulation of miR-
214 is specifically bypassed in when MAECs were treated with both MGO 
and miR-214 inhibitor.  
It is well known that PHLPP2 can directly dephosphorylate Akt to inhibit 
its signalling activity in endothelial cells (Sun et al. 2016). Once validated 
PHLPP2 as direct target of miR-214, we then verified whether the negative 
effect of MGO on the insulin signalling pathway in MAECs may be 
mediated by miR-214 downregulation, by testing the Akt phosphorylation 
levels on serine 473 following the specific inhibition of miR-214 in MAECs. 
As expected, the following increase of PHLPP2 leads to a decreased 
phosphorylation levels of Akt, thus mimicking the MGO-dependent effect 
on the insulin sensitivity in endothelial cells. Moreover, when MAECs were 
transfected with miR-214 mimic, a rescue effect on Akt activation and 
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PHLPP2 levels occurred, strengthening our hypothesis that the 
downregulation of miR-214 may contribute to the MGO-dependent effect 
through its new target, PHLPP2.  
Therefore, in this study, also provided evidence of a negative effect played 
by miR-214 on the responsiveness to insulin in MAECs, by regulating  
PHLPP2. 
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2.8 Conclusion 
 
Our study demonstrates for the first time that MGO modulates miR-190a, 
miR-450a, miR-126 and miR-214. Among these, miR-190a and miR-214 
mediate the endothelial insulin-resistance induced by MGO in MAECs, by 
targeting KRAS and PHLPP2, respectly. Thus, we indicate here both miR-
190a and miR-214 as a new players in the MGO negative effect on 
endothelial cell function. Further investigations will be useful for the 
identification of novel therapy for preserving endothelial sensitivity and 
preventing the progression of vascular complications. 
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2.9 Material and Methods 
 
Reagents 
 
Media, sera and antibiotics for cell culture were from Lonza (Walkersville, 
MD, USA). MGO (40% in water) were from Sigma-Aldrich (St Louis, MO, 
USA). U0126 was from ENZO Lifescience (Florence, Italy). Insulin was 
from Eli Lilly (Florence, Italy). The antibodies used were anti-p-thr308-Akt, 
anti-p-tyr-IRS1 (Millipore, Billerica, MA, USA), anti-p-ser616-IRS1 (Life 
Technologies, Carlsbad, CA, USA), anti-p-tyr-IR, anti-Akt, anti-p-ser473-
Akt, anti-PTEN, anti-eNOS, anti-p-ser1177-eNOS, anti-p-thr497-eNOS 
(Cell Signalling Technology, Beverly, MA, USA), anti-ERK1/2, anti-p-
ERK1/2, anti-14-3-3, anti-β-actin, anti-PTP1B and anti-Akt  (Santa Cruz, 
CA, USA), anti-KRAS (Abcam, Cambridge, UK) and anti-α-tubulin 
(Sigma-Aldrich, St Louis, MO, USA), anti-PHLPP1 and anti-PHLPP2 
(Bethly Laboratories, Montgomery, TE, USA).  All other chemicals were 
from Sigma-Aldrich (St Louis, MO, USA). Protein electrophoresis and 
western blot reagents were from Bio-Rad (Richmond, VA, USA) and 
chemiluminescence reagents from Pierce (Rockford, IL, USA). 
 
Cell Culture 
 
Mouse aortic endothelial cells (MAECs) were kindly provided by T.H 
Fleming (University of Heidelberg, Heidelberg, Germany). MAECs were 
plated in T75 flasks and grown in Dulbecco's Modified Medium (DMEM) 
containing 1 g/l glucose supplemented with 10% (v/v) FBS, 2 mmol/l L-
glutamine and 0.1 mmol/l non-essential amino acids. Cell cultures were 
maintained at 37 °C in a humidified atmosphere containing 5% (v/v) CO2. 
Cells were starved in serum-free medium containing 0.25% (w/v) albumin 
bovine serum (BSA) for 16 h, treated with MGO 500 μmol/l and then 
exposed or not to 100 nmol/l insulin for 10 min. Where indicated, cells were 
pre-treated for 30 min with U0126 15 μmol/l and then treated with MGO 
500 μmol/l for 16h. 
 
 
MiRNA Target Prediction 
 
miRWalk2.0, a comprehensive atlas of microRNA–target interactions, was 
used (Dweep and Gretz 2015) for target prediction of specific miRNAs. 
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Cell transfection 
 
miR-190a levels were modulated by transfecting MAECs with miR-190a-
mimic (mmu-miR-190a-5p miRIDIAN Mimic) 0.5 nM or with miR-190a-
inhibitor (mmu-miR-190a-5p miRIDIAN Harpin Inhibitor), miR-214 levels 
were modulated by transfecting MAECs with 0.5, 5, or 50 nmol/L miR-214-
mimic (mmu-miR-214 miRIDIAN Mimic) or miR-214-inhibitor (mmu-
miR-214 miRIDIAN Harpin Inhibitor). miR-126 levels were modulated by 
transfecting MAECs with 0.5, 5 and 50 nmol/L miR-126-mimic (mmu-miR-
126 miRIDIAN Mimic) or miR-126-inhibitor (mmu-miR-126 miRIDIAN 
Harpin Inhibitor). DharmaFECT 4 was used as transfecting agent, according 
to the manufacturer’s instructions (Dharmacon, part of GE Healthcare, 
Lafayette, CO). miRIDIAN microRNA Mimic negative control #1 and 
miRIDIAN microRNA Harpin Inhibitor Negative control #1 (Dharmacon, 
Lafayette, CO, USA) were used as negative controls of miRNA-mimic and 
miRNA-inhibitor transfection, respectively. After 48 h, the cells were 
directly harvested in the case of miR-inhibitor or harvested after MGO 
treatment and analyzed as described below. For study of miR-190a, KRAS 
protein levels were reduced in MAECs transfected with a specific siRNA 50 
nM or a siRNA with a scrambled sequence used as a negative control, both 
of which purchased from Integrated DNA Technologies (IDT, Coralville, 
IA, USA). TransIT-TKO from Mirus Bio LLC (Madison, WI, USA) was 
used as transfecting reagent, according to the manufacturer's instructions. 
 
Mice 
 
Mice Glo1-knockdown (Glo1-KD) mice were generated and characterized 
as previously described (Queisser et al. 2010, Bierhaus et al. 2012, Giacco et 
al. 2014). Mice were housed in a temperature-controlled (22 °C) room with 
a 12 h light/dark cycle, in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the National Institutes of Health 
(Marsch and Studer 1999), and experiments were approved by the ethics 
committee of the MIUR. Reduced Glo1 mRNA levels were confirmed by 
quantitative PCR. For vascular insulin signalling, a bolus of insulin (0.15 
U/g bodyweight) was i.p. administrated to mice 10 min before they were 
killed by cervical dislocation. Aortic tissues were then collected and 
processed as follow. 
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Western blot Analysis 
 
MAECs were solubilized in lysis buffer (50 mmol/L HEPES pH 7.5, 150 
mmol/L NaCl, 10 mmol/L EDTA, 10 mmol/L Na2P2O7, 2 mmol/L 
Na3VO4, 100mmol/L NaF, 10% glycerol, 1% Triton X-100) for 2 h at 4 °C. 
Protein lysates were clarified by centrifugation at 16,000× g for 20 min. Cell 
lysates were then separated by SDS-PAGE and transferred into 0.45 µm 
Protran Nitrocellulose Membrane (Sigma-Aldrich). Upon incubation with 
primary and secondary antibodies (for a full list of the antibodies, see 
above), immunoreactivity bands were detected by chemiluminescence and 
densitometric analysis was performed using ImageJ software. 
 
Measurement of NO 
 
NO was measured in cell culture medium. After treatments, culture medium 
was collected, centrifuged at 1000g for 15 min and the supernatant fraction 
was used as a sample solution for the detection, using Nitrate/Nitrite Assay 
Colorimetric Kit (Sigma-Aldrich). This assay uses the Griess reaction, 
resulting in the formation of a chromophoric azo-derivative, which absorbs 
light at 540–570 nm. 
 
miRNA reverse transcription, miScript PCR Array and Real Time-
PCR. 
 
Total RNA was isolated from MAECs and mouse aorta samples after 
homogenization in Qiazol using miRNeasy mini kit (QIAGEN, Hilden, 
Germany), according to manufacturer's instructions. After quantification 
with Nanodrop 2000 spectrophotometer (Thermo Scientific, Mirra et 2017), 
total RNA was reverse transcribed using the miScript II RT Kit (QIAGEN) 
and analyzed by the Diabetes miRNA PCR Array (QIAGEN; 
http://sabiosciences.com/mirna_pcr_product/HTML/MIMM-115Z), 
according to the manufacturer's instructions. The PCR array was provided 
in ready-to-use 96 well-plate, which contains 84 miRNA-specific primers 
and different snoRNA/snRNA specific primers, used as normalization 
controls. One plate was used for each experimental condition. Resulting data 
were analyzed by the free data analysis software, available at 
http://pcrdataanalysis.sabiosciences.com/mirna. The differential expression 
of miRNAs was then validated by Real Time-PCR using the miScript SYBR 
Green PCR Kit (QIAGEN) and specific miScript Primer Assays. The levels 
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of all differential expressed miRNAs were quantified as expression units 
relative to U6 snRNA, used as housekeeping smallRNA. Specific primers 
used for amplification were purchased from QIAGEN:  
 
Mm_miR-190_3 miScript Primer Assay, MS00032438 
Mm_miR-214_2 miScript Primer Assay, MS00032571 
Mm_miR-34a_1 miScript Primer Assay, MS00001428 
Mm_miR-126-5p_1 miScript Primer Assay, MS00006006 
Mm_miR-129-3p_1 miScript Primer Assay, MS00006013 
Mm_miR-199a-5p_1 miScript Primer Assay, MS00032529 
Mm_miR-214_2 miScript Primer Assay, MS00032571 
Mm_miR-320_3 miScript Primer Assay, MS00011767 
Mm_miR-335_1 miScript Primer Assay, MS00002142 
Mm_miR-375_2 miScript Primer Assay, MS00032774 
Mm_miR-381_2 miScript Primer Assay, MS00032802 
Mm_miR-450a_1 miScript Primer Assay, MS00025886 
Mm_miR-451_1 miScript Primer Assay, MS00002408 
RNU6B_13 miScript Primer Assay, MS00014000 
 
            
Target Site Inhibition Assays. 
 
The miScript miR-214 Target Protector (miR-214 TP) was designed based 
on the sequence of the target site for the miR-214 in the 3’UTR of the mouse 
PHLPP2 mRNA and obtained from Qiagen (Qiagen, Germantown, MD, 
USA). The miScript Target Protector is a single-stranded modified RNA 
that is complementary to the binding site of the miRNA of interest and 
covers the flanking region of the binding site, thus interfering specifically 
with the interaction of the miRNA with a single target and leaving the 
regulation of other targets of the same miRNA unaffected. After 
transfection, a miScript Target Protector binds to its specific miRNA-
binding site, blocking miRNA access the site and preventing gene 
downregulation by a specific miRNA. MAECs were co-transfected with 
both 0.1 nmol/L miR-214 TP and 50 nmol/L miR-214 mimic using 
DharmaFECT 4 (Dharmacon), according to manufacturer’s instructions. 
Forty-eight hours after transfection, cells were harvested and PHLPP2 
protein levels were analyzed as described below. 
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Luciferase Reporter Assays. 
 
The mouse PHLPP2-3’UTR sequence was inserted into pEZX-MT06, a 
Firefly/Renilla Duo-Luciferase reporter vector (GeneCopoeia, Rockville, 
MD, USA) (Carroll et al. 2014). Here, Firefly luciferase is the reporter gene 
controlled by the 3’UTR of interest and Renilla luciferase is the internal 
control. 
MAECs were plated in 6-well plates and co-transfected with 100 ng of the 
pEZX-MT06 control reporter vector or the pEZX-MT06/PHLPP2-3’UTR 
reporter vector and 50 nmol/L miR-214 mimic or a non-targeting control 
oligonucleotide (mimic control) using DharmaFECT 4 (Dharmacon), 
according to manufacturer’s instructions. Twenty-four hours post 
transfection, Firefly and Renilla luciferase activities were determined in cell 
lysates using the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI, USA) and a luminometer (Orion I, Berthold Detection 
Systems, Pforzheim, Germany) according to the manufacturer. Results were 
expressed as the ratio of Firefly to Renilla activity. The experiments were 
performed in triplicate. 
 
Statistic Procedures. 
 
Data are expressed as means ± SD and ± SEM, as indicated in figure legends. 
Comparison between groups were performed using Student’s t-test or the 
one-way analysis of variance followed by Tukey multiple comparison tests, 
as appropriate, using GraphPad Prism 6.01 software (GraphPad, San Diego, 
CA, USA). A p-value of less than 0.05 was considered statistically 
significant. 
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